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EuroFlow standardization of ﬂow cytometer instrument settings
and immunophenotyping protocols
T Kalina1,11, J Flores-Montero2,11, VHJ van der Velden3, M Martin-Ayuso4, S Bo¨ttcher5, M Ritgen5, J Almeida2, L Lhermitte6, V Asnafi6,
A Mendonc¸a7, R de Tute8, M Cullen8, L Sedek9, MB Vidriales10, JJ Pe´rez10, JG te Marvelde3, E Mejstrikova1, O Hrusak1, T Szczepan´ski9,
JJM van Dongen3 and A Orfao2 on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and
classiﬁcation of hematological malignancies by introducing 8-color ﬂow cytometry with fully standardized laboratory procedures
and antibody panels in order to achieve maximally comparable results among different laboratories. This required the selection of
optimal combinations of compatible ﬂuorochromes and the design and evaluation of adequate standard operating procedures
(SOPs) for instrument setup, ﬂuorescence compensation and sample preparation. Additionally, we developed software tools for the
evaluation of individual antibody reagents and antibody panels. Each section describes what has been evaluated experimentally
versus adopted based on existing data and experience. Multicentric evaluation demonstrated high levels of reproducibility based
on strict implementation of the EuroFlow SOPs and antibody panels. Overall, the 6 years of extensive collaborative experiments and
the analysis of hundreds of cell samples of patients and healthy controls in the EuroFlow centers have provided for the ﬁrst time
laboratory protocols and software tools for fully standardized 8-color ﬂow cytometric immunophenotyping of normal and
malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single
database.
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INTRODUCTION
Immunophenotyping is currently one of the fundamental pillars
for the diagnosis and classiﬁcation of leukemia and lymphoma.1 In
the last two decades multiparameter ﬂow cytometry has become
the preferred method to assess the immunophenotypic features
of cells present in peripheral blood (PB), bone marrow (BM), lymph
node (LN) biopsy specimens, cerebrospinal ﬂuid (CSF) and
other types of samples suspected of containing neoplastic
hematopoietic cells.1,2 During the ﬁrst part of this period, the list
of clinically useful antibodies (Abs) has progressively increased,3–5
leading to the deﬁnition of complex immunophenotypic proﬁles.
In parallel, the number of antigens that can be assessed in a single
measurement has increased dramatically owing to the availability
of new multicolor digital instruments and a greater number of
compatible ﬂuorochromes.6,7 This has facilitated more precise
identiﬁcation and phenotypic characterization of speciﬁc
populations of tumor cells in samples over the background of
the coexisting residual normal leukocyte subsets.8 However, the
higher complexity of the immunophenotypic approaches and
panels of reagents involved in such characterization demanded
increasing expertise for correct interpretation of the data
obtained. As a consequence, disturbing levels of subjectivity
have been introduced, depending on the experience and
knowledge of individual experts and the variable panels of
reagents applied in different clinical diagnostic laboratories.
In order to decrease such variability and subjectivity, consensus
recommendations and guidelines have been produced by several
expert groups.3,5,9–14 These documents have had a wide impact
and they have been followed by many centers around the world,
but they have been only partially successful for several reasons.
First, they focus on lists of markers without speciﬁc
recommendations about reagent clones, ﬂuorochrome
conjugates or optimally designed antibody combinations in the
panel. Second, they fail to provide robust protocols for the
selection of the most appropriate (i) combinations of
ﬂuorochromes and ﬂuorochrome-conjugated reagents in a
panel, (ii) sample preparation techniques, (iii) standard operating
procedures (SOPs) to establish instrument settings prior to the
measurements and (iv) the most adequate strategies for data
analysis. Most importantly, the so far proposed sets of markers
have never been prospectively evaluated.
In 2006 the EU-supported EuroFlow Consortium (EU-FP6, LSHB-
CT-2006-018708) started a project aimed at the prospective
design and evaluation of panels of antibodies for the diagnosis
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and classiﬁcation of the most frequent subtypes of leukemias and
lymphomas in which immunophenotyping has proven to be
relevant. The major objectives were (i) to provide comprehensive
multicolor combinations of ﬂuorochrome-conjugated antibodies
aimed at answering those medical questions for which multicolor
ﬂow cytometry immunophenotyping is indicated, (ii) to prospec-
tively evaluate their performance in multiple diagnostic labora-
tories and (iii) to optimize the reagent panel whenever required.
For this purpose, proven reproducibility in multiple diagnostic
laboratories was mandatory. Therefore, the deﬁnition of optimal
antibody panels also required an effort in the selection of the most
appropriate combination of compatible ﬂuorochromes, the design
and evaluation of adequate SOPs for instrument setup, ﬂuores-
cence compensation and sample preparation and elaboration of
adequate software tools for the overall evaluation of the
phenotypic proﬁles obtained.
In the ﬁrst ﬁve sections of this paper, we provide detailed
information about the selection of the most appropriate
combination of ﬂuorochromes for 8-color panels, the protocols
recommended for instrument settings, ﬂuorochrome compensa-
tion and sample preparation, together with the data analysis
strategies adopted to evaluate the tested antibody reagents and
panels. In the last section, results of multicentric evaluation of the
level of reproducibility that can be achieved by implementation of
all standardization efforts are provided. In each of the sections, we
indicate what has been speciﬁcally evaluated versus adopted
based on existing data.
SECTION 1. FLUOROCHROME SELECTION FOR 8-COLOR
PANELS
J Flores-Montero1, T Kalina2, JJ Pe´rez3, S Bo¨ttcher4,
VHJ van der Velden5, J Almeida1, L Lhermitte6, A Mendonc¸a7,
R de Tute8, M Cullen8, L Sedek9, E Mejstrikova2,
JJM van Dongen5 and A Orfao1
1USAL, Salamanca, Spain; 2DPH/O, Prague, Czech Republic; 3HUS, Salamanca,
Spain; 4UNIKIEL, Kiel, Germany; 5Erasmus MC, Rotterdam, The Netherlands;
6AP-HP, Paris, France; 7IPOLFG, Lisbon, Portugal; 8UNIVLEEDS, Leeds, UK and
9SUM, Zabrze, Poland
BACKGROUND
Selection of the most appropriate combination of ﬂuorochromes
is a key step in designing a multicolor immunophenotypic panel.15
Usage of the new digital ﬂow cytometers capable of
simultaneously measuring multiple (for example, X6) different
ﬂuorescence emissions has only recently become possible in
diagnostic laboratories because of the increasing availability of
compatible ﬂuorochromes.16–21 However, the varying spectral
overlap of such ﬂuorochromes has also led to a higher complexity
of ﬂuorescence compensation matrices.6,22,23
Fluorochrome selection largely depends on the intrinsic
characteristics of each individual ﬂuorescent compound, particu-
larly its excitation and emission proﬁle, its relative brightness, the
spillover into other ﬂuorescence detectors and its stability.24 The
selection of the most adequate ﬂuorochrome combination also
depends on the speciﬁc optical conﬁguration of the ﬂow
cytometer, that is, the number and type of laser lines it
contains, the number of detectors available for each laser and
the speciﬁc set of ﬁlters for each individual laser.7 Furthermore,
the aim of an antibody panel, the type of samples to be stained
(that is, PB, BM versus small cell samples) and the cells contained
in it also contribute to the decision on the minimum number of
reagents to be simultaneously assessed in individual tubes.25,26
Finally, the availability of optimal clones of ﬂuorochrome-
conjugated antibodies also determines the selection of speciﬁc
combinations of reagents in a panel.27,28
On the basis of the innovative immunophenotyping strategy
designed by the EuroFlow group in which new data merge and
calculation tools are combined for improved diagnosis and
classiﬁcation of hematological malignancies, a minimum require-
ment of 8-color panels for cost-effective immunophenotyping
was foreseen. Such panels should allow simultaneous usage
of (i) backbone markers aimed at speciﬁc identiﬁcation of the
cell populations of interest and (ii) additional antibody markers
devoted to a more detailed characterization of the said cell
populations.29
In this section we review the selection of ﬂow cytometer
instruments, their optical conﬁguration and the set of compatible
ﬂuorochromes, as performed during the construction and evalua-
tion of the EuroFlow 8-color panels.
Selection of ﬂow cytometry instruments and their optical
conﬁgurations
At the time the EuroFlow project started in March 2006, four
X8-color ﬂow cytometry instruments from two different manu-
facturers were available, with ﬂexible and compatible optical
conﬁgurations (Table 1), which could potentially be used in
diagnostic laboratories. The four instruments were taken into
consideration in selecting the combinations of ﬂuorochromes to
be used in the EuroFlow panels. All four instruments have a three
laser-line conﬁguration, with blue (488 nm), red (633 or 635 nm)
and violet (405 or 407 nm) lasers.
Selection of ﬂuorochromes
A two-step approach was used by the EuroFlow group for
selection of ﬂuorochromes: (i) some ﬂuorochromes were pre-
deﬁned without further speciﬁc testing based on previous
experience, whereas (ii) others were evaluated prior to their
selection. Accordingly, the ﬁrst two positions for the blue laser line
(emission at 488 nm) were pre-selected as ﬂuorescein isothiocya-
nate (FITC) and phycoerythrin (PE) because of the extensive
experience available with both ﬂuorochromes, the large number
of high-quality commercially available reagents and their compat-
ibility with the optical conﬁguration of all the four X8-color
instruments listed in Table 1. The same selection criteria were
applied for Allophycocyanin (APC) as the ﬁrst ﬂuorochrome for the
red laser line (emission at 633/635 nm). Similarly, either peridinin–
chlorophyll–protein complex (PerCP) or PerCP–Cyanin5.5
(PerCPCy5.5) and PE–Cyanin7 (PECy7) were left as the most
suitable ﬂuorochrome choices for the third and fourth detectors of
the blue laser line, respectively. In contrast, APC-Cyanin7 (APCCy7),
Alexa Fluor 700 (AF700) and APC-Hilite7 (APCH7) were compared
for the second detector of the red laser line, and Paciﬁc Blue
(PacB) versus Horizon V450 (HV450) and Paciﬁc Orange (PacO)
versus Anemonia Majano cyan ﬂuorescent protein (AmCyan)17
versus Horizon V500 (HV500) were evaluated for the ﬁrst and
second detector of the violet laser line (emission at 405/407 nm),
respectively.
For these evaluations several ﬂuorochrome-conjugated anti-
body reagents were compared: PacB-conjugated CD2(TS1/8),
CD3(UCHT1), CD4(RPA-T4), CD20(2H7), CD45(T29/33) and
HLADR(L243) versus HV450-conjugated CD2(S5.2), CD3(UCHT1),
CD4(RPA-T4), CD20(L27), CD45(HI30) and HLADR(L243); AmCyan-
conjugated CD45(2D1) versus PacO-conjugated CD45(HI30) versus
HV500-conjugated CD45(HI30); and APCCy7-conjugated CD4(RPA-
T4) versus AF700-conjugated CD4(RPA-T4) versus APCH7-conju-
gated CD4(RPA-T4) antibody(clone) reagents. Antigen expression
was evaluated as both mean ﬂuorescence intensity (MFI) and stain
index (SI; deﬁned as the difference between the MFI of positive
and negative cells divided by 2 s.d.’s of the MFI observed for the
negative cell population).24 In all cases, staining ofX5 PB samples
was used to evaluate the staining patterns of each pair/group of
reagents to be compared. Sample preparation and instrument
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settings were performed in the eight different EuroFlow
laboratories as described in Section 2 and Section 4 of this
manuscript.
Comparison between the Paciﬁc Blue (PacB) and Horizon V450
(HV450) ﬂuorochromes
The PacB and HV450 ﬂuorochromes showed very similar ﬂuorescence
proﬁles that adequately ﬁt with the optical conﬁguration of the ﬁrst
detector for the violet laser of the four ﬂow cytometry instruments.
Detailed comparison of the needs for compensation for the spillover
into other detectors of the ﬂuorescence emissions of these two
ﬂuorochromes showed that these were slightly higher (P40.05;
Mann–Whitney U test) for PacB versus HV450; nonetheless, both
ﬂuorochromes showed no spillover into any detector except for the
second detector of the violet laser (Table 2).
Regarding MFI and SI values, similar results with o10%
differences were found when the same clone and manufacturer
were compared. Conversely, when either the clones or the
manufacturers were not the same, differences between reagents
were higher (Table 3). We have chosen PacB for the EuroFlow
panels, based on broader availability of PacB conjugates at the
time of testing.
Comparison among the Anemonia Majano cyan ﬂuorescent
protein (AmCyan), Paciﬁc Orange (PacO) and Horizon V500
(HV500) ﬂuorochromes
Speciﬁc comparisons for the second detector of the violet laser
line were made for the AmCyan, PacO and HV500 ﬂuorochrome
dyes. These ﬂuorochromes showed clearly different ﬂuorescence
proﬁles. Accordingly, in terms of needs for ﬂuorescence compen-
sation, a higher spillover into other channels was observed for
AmCyan, particularly in the ﬁrst detector of the violet laser line
(Po0.01 versus both PacO and HV500; paired Student’s T-test) and
in the ﬁrst detector of the blue laser (Po0.01 versus both PacO
and HV500; paired Student’s T-test), where either PacB or HV450,
and FITC, respectively, are typically measured. Table 2 summarizes
the compensation matrix values obtained for these three dyes. In
general, the MFI obtained for monoclonal Ab reagents conjugated
with these ﬂuorochromes directed against the same antigen was
also higher for AmCyan, although different clones were compared
and ﬂuorescence differences may not be solely related to the
ﬂuorochrome (Table 3). AmCyan showed a higher resolution
power, but the higher ﬂuorescence intensity represented a
disadvantage when a strong AmCyan signal for a marker was
combined with a dim signal of FITC-conjugated reagents in the
same cell populations, because of its relatively higher overlap with
the ﬁrst detector of the blue laser (data not shown). In turn, PacO
showed low spillover into other channels (Table 2), together with
clearly dimmer MFI values (Table 3); nonetheless, its resolution
power, as reﬂected by the observed SI, was comparable to that of
AmCyan (Table 3). HV500 showed an intermediate proﬁle between
AmCyan and PacO in terms of both needs for compensation and
ﬂuorescence intensity of positive cells (higher than PacO but lower
than AmCyan), associated with a comparable resolution power (SI)
between different cell populations (Table 3).
Comparisons among the Allophycocyanin–Cyanin7 (APCCy7),
Alexa Fluor 700 (AF700) and Allophycocyanin–Hilite7 (APCH7)
ﬂuorochromes
Comparison of APCCy7, AF700 and APCH7 was performed in
sequential steps. First, the performance of each individual
ﬂuorochrome was assessed. Accordingly, APCCy7 showed a
relatively high intensity (Table 3), while its main disadvantage
was the over-time instability, especially in the presence of
formaldehyde-based ﬁxatives. This instability resulted in a
relatively high and variable degradation-associated ‘spillover’ into
the ﬁrst channel of the red laser and the appearance in thisT
ab
le
1.
Ty
p
ic
al
d
ef
au
lt
o
p
ti
ca
l
co
n
fig
u
ra
ti
o
n
an
d
m
o
st
co
m
m
o
n
flu
o
ro
ch
ro
m
es
av
ai
la
b
le
fo
r
ea
ch
d
et
ec
to
r
o
f
th
re
e
la
se
rs
,
X
8-
co
lo
r
flo
w
cy
to
m
et
ry
in
st
ru
m
en
ts
av
ai
la
b
le
in
M
ar
ch
20
06
C
h
a
n
n
el
FA
C
SC
a
n
to
II
(B
D
B
io
sc
ie
n
ce
s)
FA
C
SA
ri
a
(B
D
B
io
sc
ie
n
ce
s)
LS
R
II
(B
D
B
io
sc
ie
n
ce
s)
C
yA
n
A
D
P
(D
a
ko
/B
ec
km
a
n
C
o
u
lt
er
)
M
o
st
co
m
m
o
n
ly
a
va
ila
b
le
fl
u
o
ro
ch
ro
m
es
La
se
r
D
M
EF
La
se
r
D
M
EF
La
se
r
D
M
EF
La
se
r
D
M
EF
1
30
m
W
V
io
le
t
(4
05
n
m
)
45
0/
50
10
m
W
V
io
le
t
(4
07
n
m
)
45
0/
50
25
m
W
V
io
le
t
(4
05
n
m
)
45
0/
50
10
0
m
W
V
io
le
t
(4
05
n
m
)
45
0/
50
Pa
cB
/H
V
45
0
2
30
m
W
V
io
le
t
(4
05
n
m
)
50
2
51
0/
50
10
m
W
V
io
le
t
(4
07
n
m
)
50
2
53
0/
30
25
m
W
V
io
le
t
(4
05
n
m
)
50
2
52
5/
50
10
0
m
W
V
io
le
t
(4
05
n
m
)
50
2
53
0/
40
A
m
C
ya
n
/P
ac
O
/H
V
50
0
3
20
m
W
B
lu
e
(4
88
n
m
)
50
2
53
0/
30
13
m
W
B
lu
e
(4
88
n
m
)
50
2
53
0/
30
20
m
W
B
lu
e
(4
88
n
m
)
50
2
53
0/
30
25
m
W
B
lu
e
(4
88
n
m
)
50
2
53
0/
40
FI
TC
/A
F4
88
4
20
m
W
B
lu
e
(4
88
n
m
)
55
6
58
5/
42
13
m
W
B
lu
e
(4
88
n
m
)
55
6
58
5/
42
20
m
W
B
lu
e
(4
88
n
m
)
55
6
57
5/
26
25
m
W
B
lu
e
(4
88
n
m
)
55
6
58
5/
42
P
E
5
13
m
W
B
lu
e
(4
88
n
m
)
61
0
61
6/
23
25
m
W
B
lu
e
(4
88
n
m
)
61
3/
20
P
E-
TR
6
20
m
W
B
lu
e
(4
88
n
m
)
65
5
67
0L
P
13
m
W
B
lu
e
(4
88
n
m
)
65
5
69
5/
40
20
m
W
B
lu
e
(4
88
n
m
)
65
5
69
5/
40
25
m
W
B
lu
e
(4
88
n
m
)
65
5
68
0/
30
Pe
rC
P
/P
er
C
P
C
y5
.5
7
20
m
W
B
lu
e
(4
88
n
m
)
73
5
78
0/
60
13
m
W
B
lu
e
(4
88
n
m
)
73
5
78
0/
60
20
m
W
B
lu
e
(4
88
n
m
)
73
5
78
0/
60
25
m
W
B
lu
e
(4
88
n
m
)
73
5
75
0L
P
P
EC
y7
8
17
m
W
R
ed
(6
33
n
m
)
66
0/
20
11
m
W
R
ed
(6
33
n
m
)
66
0/
20
35
m
W
R
ed
(6
33
n
m
)
66
0/
20
60
m
W
R
ed
(6
35
n
m
)
66
5/
20
A
P
C
/A
F6
47
9
17
m
W
R
ed
(6
33
n
m
)
73
5
78
0/
60
11
m
W
R
ed
(6
33
n
m
)
73
5
78
0/
60
35
m
W
R
ed
(6
33
n
m
)
73
5
78
0/
60
60
m
W
R
ed
(6
35
n
m
)
73
5
75
0L
P
A
P
C
C
y7
/A
P
C
H
7/
A
F7
00
a
A
b
b
re
vi
at
io
n
s:
A
F,
al
ex
a
flu
o
r;
A
m
C
ya
n
,A
n
em
o
n
ia
M
a
ja
n
o
cy
an
flu
o
re
sc
en
t
p
ro
te
in
;A
P
C
,a
llo
p
h
yc
o
cy
an
in
;C
y5
.5
,c
ya
n
in
5.
5;
C
y7
,c
ya
n
in
7;
D
M
,d
ic
h
ro
ic
m
ir
ro
r;
EF
,e
m
is
si
o
n
fil
te
r;
FI
TC
,fl
u
o
re
sc
ei
n
is
o
th
io
cy
an
at
e;
H
7,
h
ili
te
7;
H
V
45
0,
H
o
ri
zo
n
V
45
0;
H
V
50
0,
H
o
ri
zo
n
V
50
0;
LP
,l
o
n
g
p
as
s;
Pa
cB
,p
ac
ifi
c
b
lu
e;
Pa
cO
,p
ac
ifi
c
o
ra
n
g
e;
P
E,
p
h
yc
o
er
yt
h
ri
n
;P
er
C
P,
p
er
id
in
in
–c
h
lo
ro
p
h
yl
l–
p
ro
te
in
;T
R
,T
ex
as
R
ed
.a
A
F7
00
re
q
u
ir
es
a
71
0/
50
em
is
si
o
n
fil
te
r.
EuroFlow standardization of ﬂow cytometry protocols
T Kalina et al
1988
Leukemia (2012) 1986 – 2010 & 2012 Macmillan Publishers Limited
channel of false-positive events (data not shown), in line with
previous observations.24 More recently, such instability has also
been related to a cell-dependent degradation phenomenon.30 In
addition, APCCy7 showed great lot-to-lot differences in brightness
and compensation needs (data not shown). AF700 showed little
spillover into this latter channel (Table 2), but this dye required the
use of a different mirror and ﬁlter –680 nm long pass (LP) and 710/
50 nm band pass (BP), respectively– than those available by
default in all four ﬂow cytometers evaluated. In addition, the
ﬂuorescence intensity of AF700 translated into suboptimal
discrimination of some antigens expressed at relatively low levels,
particularly when they were expressed on cells that had a bright
APC signal (decreased SI due to compensation-induced data
spread; data not shown). Finally, the APCH7 dye, a more stable
APC-based tandem dye with a long Stoke’s shift, was tested.
It showed a lower SI and MFI than its equivalent APCCy7-antibody
Table 2. Mean values of compensation matrices (n¼ 5) obtained at different time points in up to five different EuroFlow flow cytometer instruments
for fluorochromes compared for the same fluorescence channel
Laser channel Compensation requirements in
other fluorescence channels
PacB HV450 PacO AmCyan HV500 APCCy7 AF700 APCH7
Violet-1 NA NA 2.2±0.3* 11.5±1.5 7.5±1.6 0.2±0.3 0.1±0.1 0.1±0.3
Violet-2 27.9±2.8 23.8±2.3 NA NA NA 0.3±0.4 0.1±0.1 NR
Blue-1 0.1±0.1 0.1±0.1 0.8±0.4 17.1±2.6 2.8±1.2 0.4±0.4 0.2±0.1 0.2±0.4
Blue-2 NR 0.1±0.1 0.4±0.2 1.4±0.2 0.5±0.2 0.2±0.2 NR 0.1±0.2
Blue-3 0.1±0.1 0.1±0.1 0.5±0.2 0.4±0.1 0.3±0.2 1.2±1.0 3.6±0.7 0.6±1.2
Blue-4 NR NR 0.1±0.1 NR NR 3.3±1.9 1.3±0.3 1.7±0.8
Red-1 NR NR 0.3±0.4 NR NR 4.8±2.5 0.8±0.2 2.0±1.1
Red-2 0.1±0.1 NR 0.1±0.2 NR NR NA NA NA
Abbreviations: AF700, alexa fluor 700; AmCyan, Anemonia Majano cyan fluorescent protein; APC, allophycocyanin; Cy7, cyanin7; H7, hilite7; HV450, Horizon
V450; HV500, Horizon V500; NA, not applicable; NR, not required; PacB, pacific blue; PacO, pacific orange. Results are expressed as percentage values±s.d.
*Po0.01 versus both AmCyan and HV500 (paired Student’s T-test).
Table 3. Mean fluorescence intensity (MFI) and stain index (SI) values obtained for different sets of reagents evaluated in normal PB samples (n¼ 5)
Marker PacB HV450 P-valuea
CD2 Clone
(manufacturer)
TS1/8
(BioLegend)
S5.2 (BD B)
MFI±s.d. of
CD2þ T and NK-
cells
5741±755.7 8259±1792.8 0.02
SIc 37.0 41.4
CD3 Clone
(manufacturer)
UCHT1 (BD Ph) UCHT1 (BD B)
MFI±s.d. of
T-cells
15 774±1503.7 17 246±814.2 0.08 APCCy7 AF700 APCH7 P-valueb
SId 117.2 130.5
CD4 Clone
(manufacturer)
RPA-T4 (BD Ph) RPA-T4 (BD B) RPA-T4 (BD B) RPA-T4 (BD B) RPA-T4 (BD B)
MFI±s.d. of
CD4þ T-cells
9474±710.2 9195±408.2 0.46 13 596±686.5 4307±174.1 9910±414.3 o0.001
SIe 61.8 66.6 42.6 41.4 35.0
CD20 Clone
(manufacturer)
2H7
(eBiosciences)
L27 (BD B)
MFI±s.d. of
B-cells
30 073±3783.5 38 152±2857.4 0.005 PacO AmCyan HV500 P-valueb
SIf 219.61 222.8
CD45 Clone
(manufacturer)
T29/33 (Dako) HI30 (BD B) HI30
(Invitrogen)
2D1 (BD B) HI30 (BD B)
MFI±s.d. of
lymphocytes
30 742±824.8 53 709±2062.2 o0.001 5521±150.6 30 681±2838.3 19 157±686.3 o0.001
SIg 3.9 5.2 3.8 4.8 3.8
HLADR Clone
(manufacturer)
L243
(BioLegend)
L243 (BD B)
MFI±s.d. of
monocytes
11 509±1721.4 16 874±1934.3 0.002
SIh 47.7 64.8
Abbreviations: AF700, alexa fluor 700; AmCyan, Anemonia Majano cyan fluorescent protein; APCCy7, allophycocyanin–cyanin7; APCH7, allophycocyanin–
hilite7; BD Ph, BD Pharmingen; BD B, BD Biosciences; HV450, Horizon V450; HV500, Horizon V500; PacB, pacific blue; PacO, pacific orange. aPaired Student’s
T-test. bPo0.001 for the following comparisons: APCH7 versus AF700, AF700 versus APCCy7, APCCy7 versus APCH7, PacO versus AmCyan, PacO versus HV500
and AmCyan versus HV500 (paired Student’s T-test). cPositive reference population (PRP): CD2þ T- and NK-cells and negative reference population (NRP),
CD2 lymphocytes. dPRP, T-cells; NRP, B- and NK-cells. ePRP, CD4þ T-cells; NRP, CD4 T-cells. fPRP, B-cells; NRP, T- and NK-cells. gPRP, lymphocytes; NRP,
neutrophils. hPRP, monocytes; NRP, lymphocytes.
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conjugates (Table 3), but the major advantages of APCH7
conjugates included (i) improved stability and (ii) better compen-
sation proﬁle, while (iii) keeping the default optical conﬁguration
of the instrument unchanged. These results are illustrated by
direct comparison of APCCy7, APCH7 and AF700 conjugates of the
same CD4 monoclonal Ab clone from the same manufacturer after
staining of normal PB samples (n¼ 5) (Table 3).
CONCLUSION
Selection of appropriate ﬂuorochromes to be combined was a key
and pre-requisite step in developing the 8-color EuroFlow panels.
On the basis of existing knowledge, experience and proven
quality of evaluated reagents, several ﬂuorochromes were
pre-selected. For other ﬂuorochrome positions, extensive compar-
isons were required. Finally, we selected the combination of PacB
(or HV450), PacO (or HV500), FITC, PE, PerCPCy5.5, PECy7, APC and
APCH7. However, it should be noted that some of these
ﬂuorochromes performed at the desirable conditions, but others
(for example, APCH7) still leave room for improvement. Substitu-
tion of PacO by HV500 and PacB by HV450 might be feasible,
provided that identical clones are used, that the new reagents are
extensively compared to the reference reagents, and that new
compensation matrices are applied, which are adequate for the
selected ﬂuorochromes.
SECTION 2. EUROFLOW STANDARD OPERATING PROCEDURE
(SOP) TO ESTABLISH STANDARDIZED INSTRUMENT SETTINGS
AT MULTIPLE SITES
T Kalina1, JG te Marvelde2, VHJ van der Velden2, J Flores-Montero3,
D Thu+rner1, S Bo¨ttcher4, M Cullen5, L Lhermitte6, AS Bedin6,
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BACKGROUND
Flow cytometers are relatively ﬂexible instruments that allow
simultaneous measurement of the light scatter properties
of different types of cells and the ﬂuorescence emissions of
distinct ﬂuorophores attached to them.31 Because of their
ﬂexibility, adequate setting of instrument conditions, including
ﬁne tuning of the light scatter and ﬂuorescence detectors, is
required prior to a speciﬁc measurement, in order to establish the
optimal window of analysis. An additional goal within the
EuroFlow project was to deﬁne SOPs to establish standardized
instrument settings that would allow reproducible (identical or at
least highly comparable) measurements at different times in the
same instrument or in different instruments at the same or at
distinct sites through the application of predeﬁned scatter and
MFI values for speciﬁc reference particles. In general, with such
SOPs, all particles that will be measured should fall in the
previously deﬁned window of analysis for the light scatter and
each ﬂuorescence detector.
The EuroFlow light scatter settings aim at reaching two goals: (i)
all populations of interest (from small erythroblasts to eosinophils
and plasma cells) fall centered within the scale limits and (ii)
adequate scatter resolution between individual cell populations is
obtained, for both cell surface and intracellular staining proce-
dures. Lymphocytes were chosen as an internal biological
reference population to control for adequate placement of
instrument light scatter settings.
The EuroFlow setting of photomultiplier tube (PMT) voltages for
a ﬂuorescence detector is established at a voltage above the
electronic noise in such a way that the least autoﬂuorescent cell
type to be measured is placed at the left side of the scale, as
‘negative’ events clearly distinguishable from debris in the
multidimensional space generated, dim ﬂuorescent events can
be discriminated from the negative, and no cell- or bead-
associated ﬂuorescence measurement reaches the upper limit of
the scale.32 Each PMT is characterized by a response of accuracy to
PMT voltage measured, as the robust coefﬁcient of variation (rCV)
of a dim particle. Optimal PMT voltage is set at the beginning of
the plateau of a rCV versus PMT voltage curve.32 In this way, the
electronic noise contribution to the signal is minimal whereas
maximal dynamic range is left for the measurement of ﬂuore-
scence. At the time of writing, Cytometer Setup and Tracking (CS&T)
beads (BD Biosciences, San Jose, CA, USA) and Cyto-Cal Multiﬂuor
Plus Violet Intensity Calibrator (Thermo Scientiﬁc, Freemont, CA,
USA) are being evaluated by EuroFlow as potentially suitable
additional calibrators for long-term, multi-center studies.
In this section we summarize the most critical and relevant
steps included in the EuroFlow SOPs developed for optimal
placement of instrument settings.
Instruments and reagents
FACSCanto II (BD Biosciences) ﬂow cytometers were used in seven
centers and both an LSR II (BD Biosciences) and a CyAn ADP (Dako,
Glostrup, Denmark/Beckman Coulter, Brea, CA, USA) were used in
another center. All cytometers were equipped with three lasers
emitting at 405/407, 488 and 633/635 nm. Optical ﬁlter conﬁg-
urations were identical, with the exceptions described in Table 1.
Eight-peak Rainbow bead calibration particles (Spherotech, Lake
Forest, IL, USA) were used throughout the study for initial PMT
characterization and for setting target MFI values, as well as for
daily checks; the same master lot of beads (RCP-30-5A master lot
X02) was used throughout the study.
Placement of PMT voltages for ﬂuorescence measurements
To place PMT voltages, the following sequential steps were used:
the Rainbow 8-peak bead population showing the second
dimmest ﬂuorescence was gated and the rCV of that peak was
calculated in each ﬂuorescence channel for PMT voltages ranging
from 300 to 999 mV at increments of 50 mV.33 The optimal voltage
for each channel was ﬁrst determined on one instrument (LSR II)
and set at the beginning of the plateau phase of the curve
generated. Using the PMT value obtained in this way, the brightest
peak was gated and its ﬂuorescence intensity recorded in all
channels and then used as preliminary ‘Target MFIs’ for all other
instruments. Subsequently, veriﬁcation of PMT settings was
performed on each individual EuroFlow instrument. For
veriﬁcation of the lower boundary, PMT settings were checked
on the rCV versus PMT voltage curve, as described above for the
reference instrument. For the ‘Target MFI’ to be accepted, PMT
voltage on each instrument had to be at the plateau of the curve
for all nine instruments. Additionally, all bright markers from
the EuroFlow antibody panels29 were tested in the corresponding
channels of all instruments; if the target MFI setting resulted in
suboptimal PMT setting on any instrument, the target MFI values
were adjusted accordingly till consensus target MFI values
assuring optimal PMT settings for each instrument were reached.
Placement of instrument settings for light scatter
measurements
Fine tuning of scatter settings was based on usage of normal
human PB lymphocytes. For this purpose, 50ml of PB samples
obtained from healthy donors (after informed consent was given)
and measured within the ﬁrst 24 h after venipuncture were used
at each site. Prior to measurement, non-nucleated red cells were
lysed (10min) using 2ml of 10X FACS Lysing Solution (BD
Biosciences) and diluted 1/10 (vol/vol) in distilled water (dH2O),
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according to the recommendations of the manufacturer. Then, the
sample was centrifuged (5min at 540 g), the cell pellet was
washed with 2ml of phosphate buffer saline (PBS; pH¼ 7.4)
containing 0.5% (w/v) bovine serum albumin (BSA; SIGMA-
ALDRICH, St Louis, MO, USA) and 0.09% of sodium azide (NaN3;
SIGMA-ALDRICH), centrifuged again under the same conditions
and ﬁnally resuspended in 250 ml of PBS with 0.5% BSAþ 0.09%
NaN3, and measured in the ﬂow cytometer at a ‘low’ ﬂow rate
mode within the ﬁrst hour after sample preparation. PMT voltages
were adjusted so that forward scatter (FSC)/sideward scatter (SSC)-
gated lymphocyte singlets reached mean SSC and FSC values of
55 000±5000 and 13 000±2000, respectively.
EuroFlow instrument settings
Final PMT voltages for each ﬂuorescence channel were set for
each instrument to reach target MFI values using the brightest
peak of Rainbow 8-peak beads of the same lot. Subsequent
rainbow bead lots were assigned new target MFI values by cross-
calibration using the previous lot for an instrument in a single
laboratory (DPH/O, Prague, Czech Republic) (Table 4, see also
www.euroﬂow.org for the updated target MFI of other Rainbow
bead lots). In turn, light scatter settings were placed as described
above. Inclusion of the FSC-H parameter will allow discrimination
of doublets in a FSC-Area (FSC-A) versus FSC-Height (FSC-H)
bivariate plot, contributing further to the accuracy of the results.34
The ﬁnal instrument settings for both light scatter and
ﬂuorescence-associated PMT voltages are further referred as
EuroFlow settings. The detailed EuroFlow SOP for instrument
setup is available at the EuroFlow website (www.euroﬂow.org).
Monitoring of instrument performance
Monitoring of instrument performance was done daily (at each
cold start) after laser stabilization was allowed for 30min. Rainbow
8-peak beads were acquired under EuroFlow settings (under
‘disabled compensation’ conditions) and the MFI of the brightest
peak in each ﬂuorescence channel was compared with the
corresponding target MFI value. The following criteria had to be
reached for the instrument to pass the check: (i) MFI values within
the target MFI±15%, and (ii) coefﬁcient of variation (CV) of the
brightest peak o4% for the blue and violet laser channels, but
o6% for the red laser channels and the PECy7 channel. Whenever
instrument performance failed, measures such as thorough
cleaning, de-gassing ﬂow cell and laser delay veriﬁcation were
taken. When the performance was not restored to pass the
monitoring criteria, a service visit was requested. After a service
visit, PMT settings were adjusted as described above and a new
compensation experiment was performed as described in Section
3 of this manuscript.
MFI values of the brightest Rainbow bead peak were
daily reported for each individual ﬂow cytometer. As the scaling
of axes is different on FACSCanto II and LSR II (262 144 channels)
as compared to CyAn ADP (4096 channels), the Rainbow beads
Table 4. Target mean fluorescence intensity (MFI) values obtained
after optimal PMT adjustments for each fluorescence channel for the
brightest peak of Rainbow 8-peak calibration beads in the LSR II
instrument
Fluorochrome channel MFI values Rainbow lot no.
X02, Y02 Z02 EAB01
PacB 195 572 194 818 215 352
PacO 231 265 216 293 217 908
FITC 59 574 58 372 65 283
PE 101 900 98 520 84 847
PerCPCy5.5 216 064 223 940 228 818
PECy7 27 462 27 185 29 865
APC 176 780 226 435 252 000
APCH7 56 437 81 371 102 099
Abbreviations: APC, allophycocyanin; Cy7, cyanin7; FITC, fluorescein
isothiocyanate; H7, hilite7; PacB, pacific blue; PacO, pacific orange;
PE, phycoerythrin; PerCPCy5.5, peridinin–chlorophyll–protein–cyanin5.5.
Figure 1. Comparison of cytometer setting & tracking (CS&T)
module and EuroFlow baseline settings obtained for the fluorescein
isothiocyanate (FITC) channel (blue laser line) in one representative
instrument. CS&T (mid-fluorescence peak in a) and EuroFlow
(Rainbow beads brightest, eighth peak in b) baseline settings are
compared in c (gray and red vertical lines, respectively) for the
robust coefficient of variation (CV) and robust electronic noise
(SDEN). Note that although EuroFlow settings used lower PMT
voltages, the robust CV values (orange line) and robust SDEN values
(green line) are still in their plateau phases.
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data ﬁle was ﬁrst converted to FCS 2.0 format and then read with the
CyAn ADP’s Summit software (Dako) to calculate the corresponding
numerical values with the same distribution over the scale.
Automated baseline settings and instrument monitoring
When FACSDiVa V6.0 software with the CS&T module and BD CS&T
beads (BD Biosciences) were introduced in 2008, baseline PMT
settings were placed according to the manufacturers’ instructions for
the FACSCanto II and the LSR II instruments. Subsequently, PMT
voltage settings were adjusted manually in the CS&T module, to
create EuroFlow baseline settings. Electronic noise (SDEN) and rCV of
the dimmest CS&T bead values obtained with the two baseline
settings were compared for eight instruments (data of one
representative instrument is shown in Figure 1).
Instrument monitoring with the CS&T module was performed in
parallel to the EuroFlow instrument performance-monitoring SOP
on three different instruments (two FACSCanto II and one LSR II),
for a 3-month period. To evaluate instrument performance, we
calculated the CV of MFI values obtained for the brightest peak of
8-peak Rainbow particles.
Reproducibility of ﬂuorescence intensity measurements with
EuroFlow settings
The level of standardization of the EuroFlow settings was
evaluated at two different time points, before standardization
evaluation experiments were performed as described in Section 6.
Results of such evaluation showed nearly identical MFI values for
individual PMTs when their voltage was set to match the target
MFI ﬂuorescence channels listed in Table 4. In all eight
instruments, the CV for the MFI values obtained for the brightest
peak of Rainbow beads was systematically lower than 5.5%
(Table 5).
Long-term evaluation of the MFI signal ﬂuctuation with
ﬁxed PMT voltages revealed that in each of the eight instruments
evaluated, changes of up to±15% of the mean target MFI might
transiently occur, whereas signiﬁcant maintenance or hardware
issues were highlighted by not meeting the above-described
monitoring criteria, with deviations in these values (Figure 2).
Electronic noise level with EuroFlow settings
The SDEN level obtained with individual ﬂow cytometers using
EuroFlow settings was highly comparable to that obtained through
the CS&T module (Figure 1), except for the PerCPCy5.5 channel
(Table 6). Thus, it could be concluded that the EuroFlow approach
for PMT settings yields high-quality data with no impairment of the
quality of the results obtained, due to higher electronic noise over
individual CS&T module baseline. On average, the EuroFlow
approach set PMT voltages at lower levels (Table 6), which allows
for slightly larger dynamic ranges for measurements on the
detectors. Of note, the signiﬁcantly higher SDEN value obtained
Table 5. Variation of mean fluorescence intensity (MFI) values
obtained for the brightest bead population of the Rainbow 8-peak
beads in individual instruments placed in eight different EuroFlow
centers (seven FACSCanto II and one LSR II flow cytometers)
Fluorochrome-associated
PMT detector
Target
MFI
Mean MFIa of individual
measurements (n¼ 12)
CV
PMT 1—PacB 195 572 193 109 5.40%
PMT 2—PacO 231 265 225 152 4.63%
PMT 3—FITC 59 574 59 003 2.08%
PMT 4—PE 101 900 100 763 2.38%
PMT 5—PerCPCy5.5 216 064 215 596 2.11%
PMT 6—PECy7 27 462 27 639 3.13%
PMT 7—APC 176 780 176 190 1.68%
PMT 8—APCH7 56 437 56 610 2.16%
Abbreviations: APC, allophycocyanin; CV, coefficient of variation; Cy7,
cyanin7; FITC, fluorescein isothiocyanate; H7, hilite7; PacB, pacific blue;
PacO, pacific orange; PE, phycoerythrin; PerCPCy5.5, peridinin–chlorophyll–
protein–cyanin5.5; PMT, photomultiplier tube. aResults are expressed as
arbitrary MFI channel values scaled from 0 to 262 144.
Figure 2. Overtime stability of Rainbow 8-peak bead mean
fluorescence intensity (MFI) profile, illustrating the results obtained for
three fluorescence channels: pacific blue (PacB) channel of the violet
laser (blue dots); phycoerythrin (PE) channel of the red laser (yellow
dots); and fluorescein isothiocyanate (FITC) channel of the green laser
(green dots), for the same flow cytometer instrument upon long-term
monitoring of MFI measurements for the brightest peak of the Rainbow
8-peak beads. As shown, faulty violet laser was recognized as a source
for the decreased MFI values falling below 15% of the target MFI (boxes
A and C). Acceptable±15% range for each channel are depicted by
gray lines and a colored background. After a service visit and laser
alignment, MFI values above 15% of the target MFI were detected (box
B); thus, photomultiplier tube (PMT) voltages were adjusted at this time
point manually (closed circles). Please note that by placement of
instrument settings as per the cytometer setting & tracking (CS&T)
module the PMT could be adjusted to correct for the violet laser failure
(open circles) until the laser failed completely and was replaced.
Table 6. PMT voltages and electronic noise (SDEN) obtained with the EuroFlow settings versus the CS&T module
Fluorochrome-associated PMT detector PMT voltage SDEN P-value
a
CS&T module settings EuroFlow settings CS&T module settings EuroFlow settings
PMT 1—PacB 431 (357–490) 412 (360–460) 24.1 (20–29.8) 24 (20.6–29.1) 0.92
PMT 2—PacO 509 (414–633) 466 (395–581) 25.2 (21.3–28.1) 24.5 (20.2–27.3) 0.08
PMT 3—FITC 483 (399–555) 438 (375–518) 28.2 (25.4–31.2) 28.9 (26.2–29.7) 0.98
PMT 4—PE 462 (411–501) 395 (370–445) 30.9 (18.1–33.6) 31.1 (18.3–32.4) 0.46
PMT 5—PerCPCy5.5 543 (456–610) 522 (440–591) 28.1 (18.1–31.3) 29.1 (18.2–32.9) 0.03
PMT 6—PECy7 624 (589–757) 552 (539–707) 29 (22.1–32.6) 29.5 (20.7–31.8) 0.49
PMT 7—APC 614 (543–687) 576 (501–629) 26 (16.8–28.9) 25.9 (12.8–28.9) 0.95
PMT 8—APCH7 489 (435–662) 524 (481–687) 25.1 (17.5–36) 26 (14.1–36.6) 0.50
Abbreviations: APC, allophycocyanin; CS&T, Cytometer Setting & Tracking; Cy7, cyanin7; FITC, fluorescein isothiocyanate; H7, hilite7; PacB, pacific blue; PacO,
pacific orange; PE, phycoerythrin; PerCPCy5.5, peridinin–chlorophyll–protein–cyanin5.5; PMT, photomultiplier tube. aTwo-tailed Student’s T-test. Results are
expressed as mean (min–max) values.
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for the PerCPCy5.5 channel was still well-ﬁtted in the plateau phase
of the voltage versus SDEN curve.
CONCLUSION
The EuroFlow SOP was designed to establish and daily monitor
standard instrument settings for a common bright signal placed at
the same level in different ﬂow cytometer instruments. Overall, our
results show optimal performance at different sites and instruments
(even from different manufacturers), with early alarms for changes in
hardware components that may impact the results. At the same
time, the EuroFlow SOP avoids performing full calibration of the
instrument (including compensation) on a daily basis.
SECTION 3. DESIGN AND EVALUATION OF EUROFLOW
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BACKGROUND
Most ﬂuorochromes used in multicolor ﬂow cytometry have
relatively broad ﬂuorescence emission spectra.7,35 Therefore,
measurement of their ﬂuorescence emissions is typically not
restricted to a single ﬂuorescence channel but the emissions are
also measured in detectors other than the primary channel for a
particular ﬂuorochrome (secondary ﬂuorescence channels).7
Spectral overlap of light into secondary channels might lead to
false-positive signals. However, the proportion of light spillover
from the total ﬂuorescence emission is constant for each
ﬂuorochrome, implying that this spillover can be mathematically
calculated and subtracted.7 The term ‘ﬂuorescence compensation’
is typically used to describe this calculation and subtraction
process. In general, the speciﬁc compensation values required
depend on the spectral characteristics of the dyes, the optical
bandpass ﬁlters and dichroic mirrors mounted in the ﬂow
cytometer, the intensity of the measured signal and the speciﬁc
voltage used for the PMT where it is detected.7 In digital ﬂow
cytometers, ﬂuorescence compensation is applied after data
acquisition.36 Accurate calculation of the compensation values
for a set of ﬂuorochromes across multiple detectors is provided by
the compensation tools available in conventional ﬂow cytometry
software once applied to data derived from the ﬂow cytometric
measurement of one or more sets of single ﬂuorochrome-stained
standards/controls.36 A full compensation matrix is calculated by
the software based on each standard/control, and then it is
applied to the measured data. A prerequisite to establish
appropriate compensation settings is that the spectral
characteristics of light emissions collected in individual channels
for the standards/controls exactly match those of the dye(s) used
in the experiment. Despite this, special attention should be paid to
the fact that several currently used dyes are compound tandem
dyes, where one ﬂuorochrome serves as an acceptor of laser light
energy and transfers this energy to the second dye of the tandem
by ﬂuorescence resonance energy transfer (FRET).7 Tandem dyes
greatly enhance the Stoke’s shift of the compound ﬂuorochrome,
but their manufacturing process may lead to non-uniform spectral
characteristics of the tandems.7 Thus, tandem dyes (that is, PECy7,
APCH7) present with variable spillover light to the donor dye
channel depending on the proximity and amount of FRET
acceptor dyes used;7 this frequently translates into the need for
speciﬁc compensation controls/standards and settings for
individual 8-color combinations containing different reagents
conjugated to the same tandem dye.7 A second prerequisite for
optimal compensation settings is that standards/controls must
contain bright signals, so that the distance between the positive
Table 7. List of fluorochrome-conjugated antibodies used to set up fluorescence compensation matrices at individual centers
Generic fluorochromes and tandem fluorochromes
Generic fluorochromes Tandem fluorochromes
Generic targets Positive target
(bead or cell)
populationa
PECy7 targets Positive target (bead or
cell) populationa
APCH7 targets Positive target (bead or
cell) populationa
CD20-PacB B-cells CD2-PECy7 CD2þ T/NK-cells CD3-APCH7 T-cells
CD45-PacO Lymphocytes CD8-PECy7 CD8hi T-cells CD4-APCH7 CD4þ T-cells
CD8-FITC CD8hi T-cells CD10-PECy7b CompBead CD8-APCH7 CD8hi T-cells
CD8-PEc CD8hi T-cells CD16-PECy7 NK-cells CD9-APCH7b CompBead
CD5-PerCPCy5.5d CD5þ T-cells CD19-PECy7 B-cells CD10-APCH7b CompBead
CD8-APCc CD8hi T-cells CD45RA-PECy7 CD45RAþ T-cells CD14-APCH7e Monocytes
CD45RO-PECy7 CD45ROþ T-cells CD19-APCH7 B-cells
CD56-PECy7 NK- and CD56þ T-cells CD24-APCH7 B-cells
CD117-PECy7b CompBead CD38-APCH7 CD38hi Lymphocytes
HLADR-PECy7 B- and HLADRhi T-cells CD43-APCH7 T-cells
CD49d-APCH7 T-cells
CD71-APCH7b CompBead
CD81-APCH7 B-cells
anti-lAPCH7b CompBead
Abbreviations: APC, allophycocyanin; Cy7, cyanin7; FITC, fluorescein isothiocyanate; H7, hilite7; PacB, pacific blue; PacO, pacific orange; PE, phycoerythrin;
PerCPCy5.5, peridinin–chlorophyll–protein–cyanin5.5. aUnless otherwise indicated, the negative reference population used for each reagent was the
lymphocytes from the ‘unstained’ control tube. For more information about the specific clones used, please see van Dongen et al.29 b‘Negative’ CompBead
used as negative reference population. cThe CD8-PE and CD8-APC antibodies are not part of the EuroFlow antibody panels and might be used from any
reliable source. dThis tandem dye requires generic compensation; eArtificially CD14 monocyte population created by ‘appending’ 5000 events from the
unstained tube to this single antibody-stained tubes (SAbST) acquisition.
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and negative subsets of events used to calculate ﬂuorescence
compensation values is as high as the maximum distance in the
experimental samples to be measured. In practice, single reagent-
stained cells or mouse immunoglobulin (Ig)-capture beads are
used as compensation standards.37 It should be noted that
compensation settings must be deﬁned only after the PMT
voltage is set for the experiment, because of its impact on
ﬂuorescence intensity and spillover into secondary channels.37
In this section we describe the procedures used to design and
evaluate the compensation matrix required for routine use of the
EuroFlow panels proposed for the different 8-color combinations
of ﬂuorochrome-conjugated antibodies, deﬁned in the EuroFlow
8-color panels.29
Fluorescence compensation standards and controls
Speciﬁc subsets of PB leukocytes stained with ﬂuorochrome-
conjugated antibody reagents in single antibody-stained tubes
(SAbST) were used as standards (Table 7) to establish the
ﬂuorescence compensation matrices to be applied to ﬂow
cytometric data measured using the 8-color EuroFlow panels for
the diagnosis and classiﬁcation of leukemias and lymphomas.
SAbST were prepared as described in Section 4 for multiple single-
stained aliquots of a normal PB sample showing negative to very
bright expression of the stained reagents. In addition, reagent-
speciﬁc SAbSTs for molecules not present on normal PB cells (for
example, CD117 PECy7) were created using Ig-capture beads
(CompBead, BD Biosciences) as speciﬁc standards for these
speciﬁc reagents in the panel. Furthermore, normal and patient
samples stained with the preliminary and ﬁnal versions of the
EuroFlow panels were used to conﬁrm the utility of the calculated
compensation matrices. The speciﬁc set of reagents used for
ﬂuorescence compensation purposes varied depending on the
selected ﬂuorochrome-conjugated antibodies at each round of
evaluation of the EuroFlow panels, as described in van Dongen
et al.29 Table 7 displays the set of markers used for the ﬁnal
version of the EuroFlow panels.29
Fluorescence compensation setup
Compensation standards and controls were acquired with
FACSDiVa software or Summit software using the software
compensation tools. The setup containing the PMT voltage for
each ﬂuorescence channel and the compensation matrix calcu-
lated by the software was saved as ‘EuroFlow’ Setup into the
FACSDiVa Setup Catalog, or as ‘EuroFlow Protocol’ in Summit.
Templates were prepared for experiments and tubes labeled with
the reagents’ names beforehand, linked to the EuroFlow settings.
Thus, reagent-speciﬁc compensation was applied accurately to the
matching reagent labels, even when the compensation matrix was
recalculated. In every center, compensation setup experiments
were performed by default once a month. Whenever instrument
monitoring failed and PMT voltages were reset to match target
MFI values, the compensation setup experiment was repeated.
Comparison of ﬂuorescence compensation matrices obtained at
different days and at distinct centers
Compensation setup experiments showed that generic compen-
sation matrices could be used for all antibody reagents in the
EuroFlow panels conjugated with the PacB, PacO, FITC, PE and
APC ﬂuorochromes, as well as for the PerCPCy5.5 tandem
ﬂuorochrome (data not shown). In contrast, different values were
required for both the PECy7 and APCH7 tandem ﬂuorochromes,
depending on the speciﬁc reagent conjugates used
(Supplementary Table 1).
To evaluate and compare the ﬂuorescence compensation
settings established at different times in each center, compensa-
tion matrices were evaluated from 14 listmode data ﬁles in FCS 3.0
format, measured in seven centers (two per center); each of the
Table 8. Fluorescence compensation matrix values obtained from listmode data files (n¼ 14) generated in 7 centers at two different time points for
a total of 7 different flow cytometry instrumentsa
Secondary fluorescence channel
PacB PacO FITC PE PerCPCy5.5 PECy7 APC APCH7
Primary fluorescence channel PacB MIN 24.3 0.0 0.0 0.0
MEDIAN NA 27.7 0.0 NR 0.0 0.0 NR NR
MAX 31.0 0.2 0.6 0.1
PacO MIN 1.9 0.2 0.0 0.0 0.0 0.0 0.0
MEDIAN 2.4 NA 0.4 0.2 0.3 0.0 0.0 0.0
MAX 2.9 0.5 0.3 0.5 0.1 0.3 0.5
FITC MIN 0.0 4.8 10.0 3.0 0.2 0.0 0.0
MEDIAN 0.0 5.6 NA 12.0 3.5 0.3 0.0 0.0
MAX 0.1 6.4 16.0 4.0 0.5 0.2 0.2
PE MIN 0.0 0.0 0.2 30.1 2.2 0.0
MEDIAN 0.0 0.1 1.3 NA 32.9 2.5 0.1 NR
MAX 0.1 0.3 1.7 38.9 2.8 0.1
PerCPCy5.5 MIN 0.0 0.0 0.0 0.0 12.5 1.6 1.0
MEDIAN 0.0 0.0 0.0 0.0 NA 16.5 2.4 5.5
MAX 0.9 0.9 0.2 0.1 18.8 3.7 8.0
PECy7 MIN 0.0 0.0 0.0 0.2 0.6 0.0 3.2
MEDIAN 0.0 0.0 0.1 0.7 2.9 NA 0.0 6.8
MAX 0.4 0.6 0.5 13.1 5.7 0.9 9.1
APC MIN 1.0 0.1 8.5
MEDIAN NR NR NR NR 1.2 0.1 NA 9.6
MAX 1.4 0.2 11.6
APCH7 MIN 0.0 0.0 0.0 0.0 0.0 1.3 1.3
MEDIAN 0.0 0.0 0.0 0.0 0.0 1.5 1.8 NA
MAX 0.2 0.1 0.2 0.1 0.2 2.0 3.9
Abbreviations: APC, allophycocyanin; Cy7, cyanin7; FITC, fluorescein isothiocyanate; H7, hilite7; NA, not applicable; NR, compensation was never required;
PacB, pacific blue; PacO, pacific orange, PE, phycoerythrin; PerCPCy5.5, peridinin–chlorophyll–protein–cyanin5.5. aResults are expressed as median percentage
values and range. Median values are highlighted in bold.
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two compensation matrices used per center had been established
after a new compensation experiment (Table 8).
Overall, compensation matrices were shown to be similar in all
seven instruments evaluated (Table 8) and their variability among
instruments was similar to that observed with time within each of the
laboratories for individual instruments (P40.05, paired Student’s
T-test). Although compensation requirements depend on the speciﬁc
PMT voltage settings, overall, high spillover was detected for the
PacB into the PacO channel and for PE into the PerCPCy5.5 channel.
Furthermore, intermediate spillover was found between PerCPCy5.5
and PECy7, between FITC and PE, PECy7 and APCH7, and between
APC and APCH7 detectors (Table 8). Compensation experiments
performed 1 month apart yielded very similar compensation values
(P40.05; paired Student’s T-test).
CONCLUSION
Fluorescence compensation setup procedures were designed to
establish ﬂuorescence compensation matrices for every individual
8-color combination of ﬂuorochrome-conjugated reagents in the
8-color EuroFlow panels.29 The complexity of the procedure was
higher than desired due to the need for different compensation
values for reagents conjugated with the PECy7 and APCH7
ﬂuorochrome tandems. Fortunately, the frequency of
compensation could be set to a time interval of 1 month,
during which only minor deviations from target MFI values were
recorded on well-performing instruments, as assessed by routine
(daily) monitoring of the standard instrument settings (see Section 2).
Notably, highly stable compensation matrices were obtained at
different times among all different EuroFlow laboratories with the
proposed ﬂuorescence compensation setup SOP. This suggests
that in the future, software solutions for automated establishment
of compensation matrices to experiments performed with
adjusted PMT voltages to target MFI values may potentially be
developed and implemented.
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BACKGROUND
At present multiple protocols and reagents are available for
staining leukocytes.5,26,38–42 Most protocols include a staining
Figure 3. Illustrating example of the differences in the light scatter characteristics of the major subsets of peripheral blood leukocytes
observed for the distinct lysing solutions and staining protocols. Please note the significant reduction in the light scatter CV for the different
leukocyte populations observed with FACS Lysing Solution and a SLW protocol (red square). Events shown in the upper-left corner of each dot
plot correspond to PerfectCOUNT beads (Cytognos SL) introduced for the evaluation of cell loss. SLW, stain-lyse-wash; SLWF, stain-lyse-wash-
fix; SLNW, stain-lyse-no wash.
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step, one or more washing steps and an erythrocyte lysing step
(whenever non-nucleated red cells are present in the sample), but
for enumeration of leukocytes the washing step is frequently
omitted.5 Erythrocytes can be lysed using ammonium chloride or
other commercially available reagents, for example, FACS Lysing
Solution, QuickLysis (Cytognos SL, Salamanca, Spain) and
VersaLyse (Beckman Coulter).5 For staining of intracellular
proteins (for example, cytoplasmic (Cy)CD3, CyMPO, nuclear
(Nu)TdT) the leukocytes need to be ﬁxed and permeabilized as
well.38,42 For this purpose, several reagents, such as BD Perm/Wash
buffer (BD Biosciences), Fix&Perm (AN DER GRUB Bio Research
GmbH, Vienna, Austria), IntraStain (Dako) and IntraPrep (Beckman
Coulter), are commercially available. Cell samples other than BM
and PB, such as LN biopsies, CSF, pleural effusion ﬂuid and
vitreous humor, may need extra steps prior to the staining
procedure.43 For example, CSF samples need to be collected in
tubes with special medium in order to prevent substantial cell
loss26 and LN biopsies need to be cut into small pieces and
homogenized.41
The choice of procedure and reagents applied to stain
leukocytes depends on the aim of the experiment, but generally
the best procedure should fulﬁll the following criteria: (a) low CVs
on FSC and SSC; (b) large differences in mean channel values for
FSC and SSC between major leukocyte populations; (c) minimal
cell loss; (d) preservation of ﬂuorochrome brightness; (e) no
impact on the stability of tandem ﬂuorochromes; (f) low
background staining; (g) minimal inter-laboratory variation; and
(h) easy and fast performance. Taking this into account, the
EuroFlow Consortium has evaluated several procedures for the
staining of samples suspected of containing neoplastic hemato-
poietic cells.
Cell samples
The EuroFlow antibody panels29 are designed for diagnosis and
classiﬁcation of all major hematological malignancies. Although
most EuroFlow antibody panels are primarily designed for
evaluation of BM and/or PB samples, other samples, for
example, pleural effusions and ﬁne-needle aspirates, can be
used as well. The preferred patient materials for these panels are
discussed elsewhere.29
Erythrocyte lysing and staining procedures evaluated
Overall, four different erythrocyte lysing solutions (ammonium
chloride, FACS Lysing Solution, QuickLysis and VersaLyse) were
evaluated to assess which best fulﬁlled the above-listed criteria.
Reagents were evaluated in all eight EuroFlow centers on PB
samples obtained from 30 healthy donors, who gave their
informed consent to participate in the study. Three different
tubes were stained for each lysing solution: (1) CD4-PacB,
CD8-AmCyan, CD45-FITC, CD19-PE and CD14-APC (all from BD
Biosciences); (2) CD4-PerCPCy5.5, CD19-PECy7 and CD8-APCH7 (all
from BD Biosciences) and (3) CD19-PECy7 (from Beckman Coulter).
Brieﬂy, 50 ml of PB was incubated (15min in darkness) with the
antibodies in a ﬁnal volume of 100ml. Subsequently, the lysing
solution was added to the tube according to the instructions of
the manufacturers and incubated for 10min at room temperature
in darkness. After centrifugation (5min at 540 g), the supernatant
was discarded and the cell pellet resuspended in 2ml PBSþ 0.5%
BSA. After another centrifugation step (5min at 540 g), the
supernatant was discarded and the cell pellet resuspended in
250ml PBSþ 0.5% BSA. For tube 1, 50 ml of PerfectCOUNT beads
(Cytognos SL) was added immediately prior to the acquisition in
Figure 4. Comparison of the absolute cell counts of major leukocyte populations (a) and lymphocyte subsets (b) obtained with the four
different lysing solutions (FACS Lysing Solution, Ammonium Chloride, QuickLysis and VersaLyse Lysing Solution) evaluated in combination
with the three different staining procedures (SLNW, SLW, SLWF) tested. Results are shown as mean values (open circles) and 95% confidence
intervals (vertical lines). FACS Lyse, FACS Lysing Solution; NH4Cl, ammonium chloride; VersaLyse, VersaLyse Lysing Solution. SLW, stain-lyse-
wash; SLWF, stain-lyse-wash-fix; SLNW, stain-lyse-no wash.
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the ﬂow cytometer. All samples were acquired in a ﬂow cytometer
at four different time points (0, 1, 3 and 24 h after staining) and
data about 100 000 events per tube were recorded and stored.
Stained samples were stored at 4 1C till acquisition at the 1-, 3- and
24-h time points.
Data recorded for tube 1 included: (a) qualitative comparison
of the separation obtained among major leukocyte populations;
(b) mean FSC and SSC channel and CVs detected for eosinophils,
neutrophils, monocytes and total lymphocytes; (c) absolute
number of eosinophils, neutrophils, monocytes, CD19þ B-cells,
CD4þ T-cells and CD8hi T-cells; (d) MFI and CV values observed for
CD45 (for each cell population) and for CD19, CD4, CD8 and CD14
for CD19þ B-cells, CD4þ T-cells, CD8hi T-cells and CD14hi
monocytes, respectively. Data recorded for the other two
monoclonal Ab combinations (tubes 2 and 3) included MFI and
CVs of positive cells in the speciﬁc channel, MFI and CVs of
negative cells in the same channel, and, for the tandem
ﬂuorochromes, the ﬂuorescence signals (MFI values) in all other
channels than the primary ﬂuorochrome-speciﬁc one.
Overall, three different staining procedures were evaluated:
stain-lyse-wash (SLW), stain-lyse-wash-ﬁx (SLWF) and stain-lyse-no
wash (SLNW). The SLW procedure is described above; for the SLWF
procedure the ﬁnal cell pellet was resuspended in PBS containing
0.5% paraformaldehyde instead of PBSþ 0.5% BSA. For the SLNW
procedure, sample preparation ended after incubation (10min)
with the lysing solution without any further washing step.
Qualitative comparison of the scatter characteristics of the major
PB cell populations for the four erythrocyte lysing solutions evaluated
showed that FACS Lysing Solution and ammonium chloride yielded
the best discrimination among them, independently of the staining
procedure used. Furthermore, comparison between the three
staining procedures tested showed that CVs for both FSC and SSC
were lower and more homogeneous with the SLNW method, except
when the FACS Lysing Solution was used, which improved the FSC
and SSC CVs with the washing step (Figure 3).
In general, the SLNW resulted in the highest cell numbers,
whereas speciﬁc loss of lymphocytes (Figure 4a) and lymphocyte
subsets (Figure 4b) was observed with the SLW and SLWF
procedures. However, cell loss was signiﬁcantly lower when FACS
Lysing Solution was used (versus all other lysing reagents)
(Figure 4).
Subsequently, we evaluated the effect of the different lysing
solutions and staining procedures on the ﬂuorescence intensities.
Both the washing step and the ﬁnal ﬁxation step induced some
decrease in the MFI of all antibodies evaluated. Overall, FACS
Lysing Solution generally resulted in the highest MFI values
(Figure 5). There were no clear differences in MFI values or
spillover of ﬂuorescence emissions into secondary channels (MFI
of ‘non-speciﬁc’ channels) between the four different lysing
solutions tested.
Based on the data derived from the performance of the four
different lysing reagents and the different sample preparation
protocols, it was decided to use a stain-lyse-wash procedure with
FACS Lysing Solution for all cell surface membrane (Sm) labelings.
The detailed protocols recommended are shown in Table 9. As
displayed there, due to the presence of Igs in plasma, membrane
stainings for Ig chains (for example, Igk, Igl and Igm) required
washing steps prior to antibody incubation. Based on experience,
practical feasibility and additional testing (data not shown), it was
agreed to include NaN3 (at a concentration of 0.09%) in all
washing solutions and to ensure that all immunostainings
including SmIgs were preceded by two washing steps with
10ml PBSþ 0.5% BSA (Table 9). The latter procedure resulted in
maximal SmIg staining intensities (data not shown).
Figure 5. Comparison of the mean fluorescence intensity (MFI) values of six fluorochrome-conjugated antibodies obtained with the four
different lysing solutions evaluated in combination with the three different staining procedures (SLNW, SLW, SLWF) tested. CD45-fluorescein
isothiocyanate (FITC) was evaluated on total peripheral blood (PB) lymphocytes, CD14-allophycocyanin (APC) was evaluated on PB monocytes,
CD4-peridinin chlorophyll protein cyanin5.5 (PerCPCy5.5) was evaluated on PB CD4þ T-lymphocytes, CD8-APC hilite7 (H7) on PB CD8hi
T-lymphocytes and the two CD19-phycoerythrin cyanin 7 (PECy7) reagents were both evaluated on PB CD19þ B-lymphocytes. Results are
shown as mean values (open circles) and 95% confidence intervals (vertical lines). FACS Lyse, FACS Lysing Solution; NH4Cl, ammonium
chloride; VersaLyse, VersaLyse Lysing Solution. SLW, stain-lyse-wash; SLWF, stain-lyse-wash-fix; SLNW, stain-lyse-no wash.
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Table 9. Detailed EuroFlow Standard Operating Procedures (SOPs) for sample preparation and staining
A. Common initial procedure when the EuroFlow antibody panel includes SmIg staining
If the EuroFlow antibody panel is going to be applied to a sample that includes SmIg staining, follow these initial steps; otherwise go directly to the
backbone, surface or intracellular staining protocols (sections B, C, D, respectively):
1. Pipette 300ml of sample into a 10-ml tube (see Note 1). Note 1: For small samples (i.e. CSF, vitreous aspirates) spin down the total volume
(5min at 540 g), discard the supernatant (see point 5) and resuspend in 300ml of PBSþ 0.5% of bovine serum albumin (BSA)þ 0.09% sodium
azide (NaN3).
2. Add 10ml filtered PBSþ 0.5% BSAþ 0.09% NaN3
3. Mix well
4. Centrifuge for 5min at 540 g
5. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet
6. Add 10ml PBSþ 0.5% of BSAþ 0.09% NaN3 to the cell pellet
7. Mix well
8. Centrifuge for 5min at 540 g
9. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet
10. Resuspend the cell pellet in 200 ml of PBSþ 0.5% BSAþ 0.09% NaN3
11. Continue with conventional EuroFlow SOPs for staining of cell surface or cell surface plus intracellular markers as described below in
procedures B, C and D, respectively
B. Staining of backbone markers
1. Calculate the total volume of surface membrane backbone antibodies based on the number of tubes in the panel (see Note 2).
Note 2: Intracellular backbone markers should not be added here.
2. Pipette these antibodies in one tube (backbone tube)
3. Calculate the total volume of sample to be stained, also based on the number of tubes in the panel and a volume of 50ml per tube
4. Pipette this sample volume into the backbone tube
5. Mix well
6. Pipette equal amounts of the sample/backbone mix into the various tubes included in the applied EuroFlow panel (see Note 3).
Note 3: Both the volume pipetted into each tube and the overall number of tubes depends on the specific EuroFlow panel that is applied.
7. Continue with the steps described below in procedure C
C. Staining of surface markers only (see Note 4):
Note 4: PCD tube 2 is processed identically to PCD tube 1 as described in section D if CD138-PacO is used.
1. Add the appropriate volume of antibodies directed against cell surface markers (except for the backbone markers), as recommended for each
specific EuroFlow panel
2. If necessary, use PBSþ 0.5% BSAþ 0.09% NaN3 to reach a final volume of 100ml per tube (see information on the EuroFlow panels)
3. Mix well
4. Incubate for 15min at room temperature (RT) protected from light
5. Add 2ml of 1x FACS Lysing Solution (10x FACS Lysing Solution diluted 1/10 vol/vol in distilled water (dH2O))
6. Mix well
7. Incubate for 10min at RT protected from light
8. Centrifuge for 5min at 540 g
9. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet, leaving approximately 50 ml residual
volume in each tube
10. Add 2ml of PBSþ 0.5% BSAþ 0.09% NaN3 to the cell pellet
11. Mix well
12. Centrifuge for 5min at 540 g
13. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet, leaving approximately 50ml residual
volume in each tube
14. Resuspend the cell pellet in 200 ml PBSþ 0.5% BSAþ 0.09% NaN3
15. Acquire the cells after staining or (if not immediately acquired) store at 4 1C maximally for 3 h until measured in the flow cytometer
D. Combined staining of intracellular and surface membrane markers (see Note 5):
Note 5: Tube 4 of the AML/MDS panel should be stained/processed further as described in Procedure E
1. Add the appropriate volumes of antibodies for cell surface markers, as recommended for each specific EuroFlow panel
2. If necessary, use PBSþ 0.5% BSAþ 0.09% NaN3 to reach a volume of 100 ml per tube (see information on the EuroFlow panels)
3. Mix well
4. Incubate for 15min at RT protected from light
5. Add 2ml of PBSþ 0.5% BSAþ 0.09% NaN3 to the cell pellet
6. Mix well
7. Centrifuge for 5min at 540 g
8. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet, leaving approximately 50 ml residual
volume in each tube
9. Resuspend the cell pellet by mixing gently
10. Add 100ml of Reagent A (fixative; Fix&Perm, An der Grub, Vienna, Austria)
11. Incubate for 15min at RT protected from light
12. Add 2ml of PBSþ 0.5% BSAþ 0.09% NaN3 to the cell pellet
13. Mix well
14. Centrifuge for 5min at 540 g
15. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet, leaving approximately 50ml residual
volume in each tube
16. Resuspend the cell pellet by mixing gently
17. Add 100ml of Reagent B (permeabilizing solution; Fix&Perm)
18. Mix well
19. Add the appropriate volume of the intracellular antibodies (see EuroFlow panels)
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Intracellular stainings
For the staining of intracellular antigens, special procedures are
needed to permeabilize and ﬁx the cells.38,42 On the basis of the
extensive experience of the EuroFlow laboratories, the Fix&Perm
reagents were selected for this purpose; no additional comparison
with other commercially available reagents was performed. The
detailed protocols are shown in Table 9.
Although the Fix&Perm reagents work well for NuTdT staining,
it was decided that within the acute myeloid leukemia (AML)/
myelodysplastic syndrome (MDS) protocol, staining of NuTdT will
be done using FACS Lysing Solution, based on the performance
previously reported,38 because all tubes can then be treated
in a similar way and additional effects on the light scatter
characteristics of leukocytes (which could potentially hamper their
use as common parameters to every stained aliquot) are avoided.
This was not applied to staining of NuTdT in the BCP-ALL and
T-ALL panels,29 because in such cases additional stainings for
other intracellular markers were required (that is, CyIgm, CyTCRb
and CyCD3), for which Fix&Perm reagents already was shown
to be of utility.38,42
To ensure similar staining intensities of the backbone markers in
all tubes (for both membrane and intracellular stainings), all
antibodies were titrated for a total volume (antibodies and
sample) of 100 ml in every tube. If this volume was not reached,
PBSþ 0.5% BSAþ 0.09% NaN3 was added to increase the volume
to 100 ml. In some EuroFlow tubes, the total volume exceeded
100ml. This was accepted as long as the total volume remained
below 115ml, as such minor deviations had no impact on the
staining intensities of the backbone markers (data not shown).
Processing of cell samples with low nucleated cell counts
As described above, the sample preparation protocols and the
different lysing solutions tested here were evaluated for the
staining of whole BM and PB samples. However, in some patients
the cell count may be rather low. This occurs, for example, in a
substantial number of pediatric MDS patients and certainly will
occur in samples obtained during therapy. We therefore evaluated
whether it was possible to perform bulk lysis of erythrocytes with
ammonium chloride prior to the EuroFlow protocol, to increase
considerably the concentration of nucleated cells in the sample.
Initially, within the AML/MDS panel,29 slight differences were
observed for CD16, CD11b and CD15, but after titration of
antibodies, ﬂuorescence emissions were highly comparable
Table 9. (Continued)
20. Mix well
21. Incubate for 15min at RT protected from light
22. Add 2ml of PBSþ 0.5% BSAþ 0.09% NaN3 to the cell pellet
23. Mix well
24. Centrifuge for 5min at 540 g
25. Discard the supernatant using a Pasteur pipette or vacuum system without disturbing the cell pellet, leaving approximately 50 ml residual
volume in each tube
26. Resuspend the cell pellet in 200ml PBSþ 0.5% BSAþ 0.09% NaN3
27. Acquire the cells after staining or (if not immediately acquired) store at 4 1C maximally for 3 h until measured in the flow cytometer.
E. Nuclear (Nu)TdT staining (Tube 4 AML/MDS EuroFlow panel):
1. Continued from procedure C step 13
2. Add the appropriate amount of the TdT antibody to the cell pellet
3. Mix well
4. Incubate for 15min at RT protected from light
5. Add 2ml of PBSþBSA 0.5%þ 0.09% NaN3 to the cell pellet
6. Mix well
7. Centrifuge for 5min at 540 g
8. Resuspend the cell pellet in 200ml PBSþ BSA 0.5%þ 0.09% NaN3
9. Acquire the cells after staining or (if not immediately acquired) store at 4 1C maximally for 3 h until measured in the flow cytometer.
Overview of protocol Sections for the various EuroFlow antibody panels and corresponding tubes.
Antibody panel Tube(s) Protocol procedure
A B C D E
ALOT 1 X
BCP-ALL 1,4 X X X
2,3 X X X
T-ALL 1–4 X X
AML/MDS 1–3, 5–7 X X
4 X X X
LST 1 X X
SST 1 X X
PCD 1–2 X X
B-CLPD 1–4 X X X
T-CLPD 1,2,4,6 X X
3,5 X X
NK-CLPD 1,2 X X
3 X X
Abbreviations: ALOT, acute leukemia orientation tube; AML/MDS, acute myeloid leukemia and myelodysplastic syndrome; BCP-ALL, B-cell precursor acute
lymphoblastic leukemia; CLPD, chronic lymphoproliferative disorder; LST, lymphoid screening tube; PCD, plasma cell disorders; SST, small sample tube; T-ALL,
T-cell acute lymphoblastic leukemia.
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between both procedures (Figure 6). Therefore, bulk lysis may be
used prior to antibody staining when nucleated cell concentration
needs to be increased, such as for the AML/MDS EuroFlow panel.29
As low cell counts less likely occur in other hematological diseases
at diagnosis, prior bulk lysis was not speciﬁcally tested for these
protocols.
Sample acquisition in the ﬂow cytometer
As the time between staining of the samples and data acquisition
in the ﬂow cytometer may have an impact on the MFI of individual
markers (particularly of those detected by reagents containing
tandem ﬂuorochromes), we acquired the samples immediately
after staining, as well as 1, 3 and 24 h after sample preparation was
completed. Our results show that MFI generally decreased over
time, particularly when lysing solutions that did not contain
ﬁxative (that is, ammonium chloride) were used (Figure 7a). The
most stable results were obtained with FACS Lysing Solution
combined with either the SLNW or the SLW procedures
(Figure 7b). Data became somewhat more variable when acquired
3 h and particularly 24 h after staining (Figures 7a and b).
On the basis of the results reported above, it was agreed that all
samples should preferably be acquired within 1 h after completing
the staining procedure. If not measured immediately, they should
be stored at 4 1C in the darkness. Samples should be acquired on
ﬂow cytometers that have been set up according to the EuroFlow
SOPs as described in Sections 2 and 3. For the EuroFlow screening
and orientation tubes (acute leukemia orientation tube (ALOT),
lymphoid screening tube (LST), small sample tube (SST) and
plasma cell dyscrasia (PCD)),29 a minimum of 50 000 cells (typically
100 000) should be acquired in order to reach sufﬁcient sensitivity
for recognition of abnormal populations.
CONCLUSION
The EuroFlow protocols for sample preparation and staining were
designed based on previous experience and experimental data
available in the literature together with the results of speciﬁc
experiments performed by the EuroFlow Consortium. Based on
the combined results, the EuroFlow Consortium favors the use of a
SLW procedure with FACS Lysing Solution for cell surface antigens,
where measurements are performed shortly (o1 h) after sample
preparation is completed. Special situations were envisaged for
the staining of SmIgs, intracellular markers and samples with low
nucleated cell counts, where introduction of additional washing
steps, a ﬁxation/permeabilization step and bulk lysis prior to
staining, respectively, are recommended. The EuroFlow sample
preparation and staining protocols described here are designed to
be used together with EuroFlow SOPs for instrument setup
(Section 2) and ﬂuorescence compensation (Section 3) for the
selected ﬂuorochromes (Section 1). The proposed sample
preparation and staining protocols perfectly ﬁt with the EuroFlow
antibody panels designed for the diagnosis and classiﬁcation of
hematological malignancies29 when using the most common
types of samples, such as PB and BM. Speciﬁc issues related to
other types of samples that have peculiar features and require
unique sample preparation protocols (for example, CSF) are
addressed in the EuroFlow antibody panel report.29
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BACKGROUND
Even though we have seen considerable improvements of clinical
ﬂow cytometry over the last years, the multicolor capabilities of
currently available ﬂow cytometers are still far behind the
requested needs in routine clinical diagnostic laboratories. For
example, the current immunophenotypic diagnosis of distinct
WHO categories of hematological malignancies frequently
requires the assessment of B30 different markers on neoplastic
cells, which cannot be routinely studied on the same cell, owing to
technical limitations.44–47 In order to overcome these technical
limitations, multiple aliquots of a sample are stained with different
combinations of markers.47 In this approach, a few markers aim at
the reproducible deﬁnition of the cell population(s) of interest; the
so-called backbone markers are repeatedly used in every aliquot
of the same sample and combined with other sets of markers,
which together aim at the detailed immunophenotypic
characterization of the cell population(s) of interest.47
Despite their clear beneﬁts, these advances in multiparameter
ﬂow cytometry have led to a signiﬁcantly increased complexity of
data analysis and data interpretation because of the higher
Figure 6. Parameter band plot of all individual parameters evaluated
in a bone marrow sample from an MDS patient treated according to
the EuroFlow protocol with (light colors) or without (dark colors)
prior bulk lysis. Colored circles represent median scatter and
fluorescence intensity (MFI) values obtained for the lymphocytes
(dark green/light green), monocytes (red/orange) and neutrophils
(dark blue/light blue).
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number of parameters simultaneously assessed in greater
numbers of individual cells, and the expanded number
of variables that might have an impact on the quality of the
results.44–47 Moreover, these technical improvements have not
been paralleled (or followed) by innovations of data analysis and
interpretation tools in the software packages routinely used in
hematology laboratories. This lack of innovation has further
contributed to the increased complexity of immunophenotyping
of hematological malignancies.44,45 In recent years, the EuroFlow
Consortium has proposed several new data analysis tools48–50
aimed at decreasing such complexity through the development of
new and more objective data analysis and interpretation
strategies.48–51 These novel tools have been progressively
incorporated into the Inﬁnicyt software (Cytognos SL) developed
by the EuroFlow Consortium.
In this section we describe the new data analysis strategy
proposed by the EuroFlow Consortium to be used in combination
with the EuroFlow antibody panels and the EuroFlow SOPs for
multiparameter immunophenotypic diagnosis and classiﬁcation
of hematological disorders.
Merge of ﬂow cytometry data ﬁles and calculation of
’missing values‘
The EuroFlow antibody panels are composed of multiple 8-color
combinations of antibodies that contain three or four ﬂuoro-
chrome-conjugated antibodies as common backbone markers,
essential for gating the cells of interest in every aliquot of a
sample stained with a speciﬁc EuroFlow antibody panel.29 The
Merge function (ﬁrst step in Figure 8) was used to fuse different
data ﬁles corresponding to distinct aliquots of the same sample,
each stained with a unique combination of reagents from the
EuroFlow antibody panels. This results in a new single merged
data ﬁle that contains all information measured in the same
sample.52,53 Such data ﬁle consists of a data matrix (Figure 9) in
which the information (the measured parameters) for each
different cellular event evaluated is aligned in one column per
Figure 7. Effect of time between completion of staining and data acquisition in the flow cytometer (0 h, 1 h, 3 h and 24 h) and the sample
preparation protocol on the mean fluorescence intensity (MFI) of CD19-phycoerythrin cyanin 7 (PECy7), CD4-peridinin chlorophyll protein
cyanin5.5 (PerCPCy5.5) and CD8-allophycocyanin hilite7 (APCH7) on peripheral blood (PB) B-cells, CD4þ T-cells and CD8hi T-cells, using
ammonium chloride (a) or FACS Lysing Solution (b) as lysing reagents. Three different sample preparation protocols were evaluated: SLNW;
SLW and SLWF. Results are shown as mean values (open circles) and 95% confidence intervals (vertical lines). FACS Lyse, FACS Lysing Solution;
NH4Cl, ammonium chloride. SLW, stain-lyse-wash; SLWF, stain-lyse-wash-fix; SLNW, stain-lyse-no wash.
Figure 8. Flow chart diagram illustrating the sequential steps used
during data analysis for the evaluation of the performance of the
EuroFlow antibody panels.
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tube, which includes light scatter- and ﬂuorescence emission-
associated parameters, placed in different rows of the data matrix.
The data matrix contains ﬁlled and unﬁlled boxes, corresponding
to parameters that were directly measured and parameters not
evaluated directly (missing values) for an individual event in a
given aliquot of the sample, respectively48 (Figure 9).
A calculation function was used to ﬁll in the ‘missing values’ in the
above-mentioned data matrix corresponding to the merged data
ﬁle. For this purpose, the common backbone parameters were used
for identiﬁcation of the neoplastic and/or normal cell populations of
interest present in each of all tubes coming from a single sample
(second step in Figure 8). Afterwards, a new data ﬁle was created,
which only contained information about those parameters mea-
sured for individual events contained in the gated cell population.48
Then, the ‘missing values’ in the data matrix corresponding to the
gated cell population were calculated (third step in Figure 8). For this
latter purpose, for each event to be calculated inside the selected
population, the software searches for the ‘nearest neighbor’54,55
event in each of the other aliquots of the sample, based only on its
unique position in the multidimensional space created by all
common backbone parameters (Figure 10). Therefore, the ‘nearest
neighbor’ of each event to be calculated in a merged data ﬁle
measured in one sample aliquot will be the event showing the
shortest distance from it in the n-dimensional space generated by
the same common parameters in another sample aliquot from the
merged data ﬁle. Finally, the software applies the values obtained
for the ‘nearest neighbor’ for all those parameters measured for the
event in the latter sample aliquot but not measured in the former
sample aliquot. This calculation process is done for each individual
event in the merged data ﬁle till the data set is completed. At the
end of the calculation process, the new data ﬁle contains both the
data that were actually measured in the ﬂow cytometer for each
event and the calculated data for those parameters not measured in
the same group of events in the other aliquots.48 The calculation
process requires optimal deﬁnition with maximum biological
heterogeneity within the cell population to become apparent with
the common parameters (for example, backbone parameters) for
the cell population to be calculated; thus, backbone marker
selection is crucial. In order to obtain a high accuracy of the
calculation process, each event in the cell population of interest is
required for its deﬁnition in the EuroFlow antibody panels, based on
ﬁve or six backbone parameters (two scatter parameters and three
to four ﬂuorescence markers).
As previously described in this paper (see Section 4), EuroFlow
antibody panels include both surface and intracellular stainings.
Therefore, variations in the FSC/SSC values or in the ﬂuorescence
levels of the backbone markers may occur because of the different
sample preparation procedures (Table 9). In order to allow the
calculation process when cells are treated with different staining
protocols, a harmonization procedure was developed56 and
applied to those cell populations of interest, for all parameters
measured in common in the different sample aliquots, which are
prepared differently (Figure 11). Such harmonization process
consists of the translation of a data matrix deﬁned in a tube by a
given set of parameters for a given cell population into a data
matrix deﬁned by the same parameters for the same cell
population measured in another tube under different conditions
(for example, surface versus surface plus intracellular stainings).
Of note, this harmonization tool did not affect the calculation
process, as similar results were obtained when we compared the
calculated values in ﬁles that contained information about a
sample for which some aliquots/tubes were submitted to
intracellular staining procedures and others were treated for Sm
staining only.
As an end result of the calculation procedure, all individual
events from each of the original data ﬁles corresponding to
different aliquots of the same sample contain information about
each reagent/parameter included in the whole antibody panel.
The overall number of parameters for which values can be
assigned to each individual cellular event included in the new
data ﬁle are virtually unlimited, and equals that of the number of
parameters measured in the whole set of merged data ﬁles for a
given number of stained aliquots of a sample. This allows
visualization of previously ‘impossible’ bivariate dot plots for
individual events (for example, staining patterns for two reagents
conjugated with the same ﬂuorochrome) 48 (Figure 10).
Generation of reference data ﬁles
A reference data ﬁle is a data ﬁle constructed by merging two or
more data ﬁles, each corresponding to a cell population measured
in different samples with the same panel of reagents (fourth step in
Figure 8). Hereby, the reference data ﬁle contains information about
all parameters (measured or calculated) for each individual event of
the targeted cell population.50 Reference data ﬁles may contain
information about normal or neoplastic cell populations, which may
be homogeneous or heterogeneous with regard to different
parameters evaluated. The generation of the reference data ﬁles
aims at building libraries of reference cases to be compared
between each other or with a new case that has been stained with
the same panel of reagents (ﬁfth step in Figure 8). On the basis of
the existence of different patterns of protein expression in normal
versus neoplastic cells, as well as among different WHO disease
entities, a library can be built, which contains all normal and
aberrant patterns that represent each of the different normal and
pathological cell populations studied with the different EuroFlow
Figure 9. Data matrix obtained from the EuroFlow B-CLPD (B-cell
chronic lymphoproliferative disorders) antibody panel, showing
merging of five original data files into a single data file containing
data about 29 parameters (2 scatter parameters and 27 markers).
Columns correspond to the different B-CLPD tubes (sample aliquots)
measured and rows correspond to the different parameters
evaluated. ‘C’ means ‘common’ marker defined as measured in all
aliquots; ‘R’ means ‘real’ data measured in any of the tubes. Blank
spaces represent the parameter information that was not measured
on an individual aliquot of the sample.
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antibody panels. Such a library can be used for (1) further
evaluation of the utility and performance of antibody panels and
(2) pattern-guided prospective classiﬁcation of new cases diag-
nosed in different individual laboratories, which use the same
EuroFlow antibody panels and laboratory procedures.50
Evaluation of the EuroFlow antibody panels based on comparisons
of groups of reference data ﬁles
The EuroFlow 8-color antibody panels for the diagnosis and
classiﬁcation of hematological malignancies are designed to
answer speciﬁc clinical questions, which can be grouped into
two general categories: (1) Is a given hematopoietic cell
population normal or reactive/regenerating or abnormal/neoplas-
tic? (2) When an abnormal/neoplastic cell population is identiﬁed,
which WHO disease category does it belong to? In order to
evaluate the utility and performance of the EuroFlow antibody
panels, different groups of reference ﬁles that had been stained
with the same antibody panels have been constructed. To answer
the ﬁrst question, reference data ﬁles from a normal/reactive cell
population were compared with their neoplastic counterpart from
Figure 10. Schematic representation of the data calculation process with the Infinicyt software based on the ‘nearest neighbor’ principle. First,
one event from a cell population (B-cells highlighted in red) in a is identified in a first data file (tube 2 of B-cell chronic lymphoproliferative
disorders (B-CLPD) panel) based on the backbone markers; then the event corresponding to the nearest neighbor of this event is identified in
the second data file (right; tube 5 of B-CLPD panel) as that event occupying the same (closest) position in a multidimensional space formed by
the same backbone parameters (b). Third, through the data calculation process the values for those parameters that were only measured
for the later event in the second data file (d) but not for the former event in the first data file are assigned to the said event in the first data file
and vice versa (c). Finally, the calculation process is completed for all other events in the cell population of interest (red events). Through this
approach, all events in the merged and calculated data file have information about each of the parameters measured in both tubes (e).
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one or multiple WHO disease entities in a multivariate 1 1 set of
comparisons approach. To answer the second question, reference
data ﬁles corresponding to the neoplastic cell population from
multiple cases of a single WHO disease entity were compared
against single or multiple reference data ﬁles corresponding to
one or more WHO disease entities.
For such comparisons, multiple approaches such as principal
component analysis (PCA) can be used with the corresponding
multiple-dimensions (that is, bi- or tridimensional) graphical
representations of, for example, Principal Component (PC) X
versus PC Y, and PC X versus PC Y versus PC Z, respectively, using
the Automatic Population Separator (APS) graphical representa-
tion of the Inﬁnicyt software (Figure 12).
On the basis of this APS representation, information about the
separation between the two groups of reference data ﬁles is
obtained through deﬁnition of median and/or mean±s.d. borders
(Figure 12) together with information about the most informative
(versus redundant) parameters.57 It also allows re-evaluation of a
panel after excluding one or multiple markers to objectively evaluate
the contribution of each marker. A similar approach can then be used
to prospectively compare one new case against two different groups
of reference data ﬁles. Through such comparison, information is
obtained about whether new cases belong to one of the reference
groups or whether they differ from the reference groups, for those
markers which are relevant in such comparison.
Through such comparisons one can also easily and objectively
identify the phenotypic differences and similarities between the cell
populations compared in the different reference groups and the
markers that account for them. In fact, it allows direct (multivariate)
comparisons of one or more cell populations from a given sample
with other (for example, reference) cell populations from a pool of
X2 different samples (Figure 12). In a certain way, this mimics what
an expert follows in his mind when he compares the immunophe-
notypic proﬁles obtained with a given antibody panel in a sample
with the proﬁles obtained for the same combinations of antibodies
in another sample (or group of samples) composed of normal,
reactive, activated, aberrant or malignant cells. For example, the
APS comparison of normal with malignant B-cell precursors allows
identiﬁcation of the best combination of markers to distinguish
between them and thereby deﬁne the most common aberrant
Figure 11. Illustrating example of the impact of different sample preparation protocols on the immunophenotypic and light scatter features of
lymphocytes from a normal peripheral blood (PB) sample (a) and blast cells from B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
(n¼ 9; c) and how the harmonization process reduces such impact (b and d, respectively). In a and b, FSC versus SSC representation of
duplicates of a sample stained with two different protocols (permeabilized versus non-permeabilized lymphocytes) is shown without (a) and
with (b) data harmonization applied, respectively; in both a and b, green and violet populations correspond to non-permeabilized and
permeabilized aliquots, respectively. In c and d, different BCP-ALL blast cell populations from nine different BCP-ALL patients each stained in
five different aliquots with the BCP-ALL EuroFlow panel are displayed. Each population is represented as median values in a principal
component (PC) 1 versus PC2 analysis diagram (automatic population separator (APS)1 view based on the discrimination obtained for the
following parameters: FSC, SSC, CD19, CD34 and CD45), where paired duplicated samples are colored identically. In c samples contain both
permeabilized and non-permeabilized aliquots within the panel and the harmonization process was applied for five patient samples
(duplicates colored dark yellow, light green, dark violet, red and cyan) for which duplicates show a very close position in the APS1 view;
conversely for the other pairs of duplicates (light yellow, dark green, violet, dark blue show greater differences between paired samples). In d,
one group of duplicates was processed by permeabilizing all aliquots within the panel, while in the other group each sample contained
permeabilized and non-permeabilized sample aliquots, with data harmonization being applied to the latter group; note that now all pairs of
sample duplicates overlap, confirming that with data harmonization blast cell populations processed differently (permeabilized versus non-
permeabilized) are highly comparable to those who underwent a uniform sample preparation protocol.
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phenotypes. In addition, APS comparison between malignant
B-cells from patients with different B-cell chronic lymphoproli-
ferative disorders (B-CLPD) deﬁned according to the WHO 2008
classiﬁcation1 allows identiﬁcation of the most informative
parameters for their differential diagnosis. Noteworthily, fully
objective information is obtained through this approach about the
speciﬁc contribution of each marker in the panel.49
CONCLUSION
During the last 6 years, the EuroFlow Consortium has built new
approaches for data analysis, which provide a new objective
strategy for evaluation of the performance and utility of individual
markers and antibody panels. The newly proposed strategy for
data analysis of samples stained with the EuroFlow antibody
panels includes a set of sequential steps (Figure 8): merge of data
ﬁles corresponding to individual samples stained with the
EuroFlow antibody panels, calculation of missing values for the
cell populations of interest, merge of data ﬁles for the reference
groups and evaluation of antibody panels through multiple
comparisons between different sets of reference cases stained
with the same panel of reagents. This new analytical strategy also
provides a pattern-guided approach for the immunophenotypic
classiﬁcation of normal and malignant cell populations.49,50 The
tools required to use the new analytical approach have been
implemented into the Inﬁnicyt software by the EuroFlow
Consortium, which allows their usage in routine practice by any
other group around the world. Herewith a full set of ﬂow cytometry
data analysis tools is provided to the ﬂow cytometry ﬁeld to help
expert-based interpretation of highly complex multiparameter data
sets. In combination with the reference data ﬁles generated, the
new software tools also provide a robust and reliable method for
data comparison between different diagnostic laboratories on a
sample-by-sample basis. The robustness and reliability of this
approach is also based on the use of antibody panels with sufﬁcient
and adequate backbone markers that have been selected for
careful identiﬁcation of the subset of cells of interest, which is
essential for accurate calculation of missing data and their graphical
representation. Accordingly, use of the EuroFlow antibody panels
and the EuroFlow SOPs for sample preparation allows for (1)
building databases with reference groups of well-deﬁned WHO
categories; (2) classiﬁcation of a new case; (3) assuring internal and
external quality control by any other user if the same tools and
reference groups are used. Therefore, the new software tools
contribute signiﬁcantly to the standardization of ﬂow cytometry
data analysis.
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BACKGROUND
In order to design and apply the EuroFlow antibody panels for the
immunophenotypic diagnosis and classiﬁcation of leukemias and
lymphomas, SOPs were developed and evaluated as described in
the previous sections. However, multicentric implementation of
such antibody panels29 and SOPs would require further evaluation
of the protocols at the multicentric level. For this purpose two
different series of experiments could be envisaged: (1) staining of
comparable samples with the same SOPs and antibody panels at
Figure 12. Example of principal component (PC1 versus PC2) analysis (PCA; automatic population separator (APS)1 views) for comparison of a
new sample—red circles (median values) and dots—with a library of cases (median values/case represented as circles) from three different reference
groups, each being colored differently (green, cyan and violet circles). In the upper panels the unknown case is compared to each pair of reference
groups and it only overlaps systematically with the dark blue cases (a–c). In the lower panels (d–f ), the new sample is separately compared with
each individual reference group, showing again a high degree of overlap with the dark blue reference cases (f ). Contour lines in each panel
correspond to one (inner line) and two (outer line) s.d.’s of the mean value of the corresponding group of reference cases.
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multiple sites, and (2) staining of the same sample at different sites
with the EuroFlow antibody panels and SOPs.
Results of the multi-step procedure to standardize EuroFlow
setup of all instruments were evaluated on a set of PB samples
following the two approaches. The variation observed in multi-
center experiments may be caused by multiple factors. Among
them, the most relevant ones include (1) the pattern of expression
of the molecule investigated (that is, tight peaks for CD4 expression
versus non-homogeneous expression of CD27 in T-cells); (2) stability
of the ﬂuorochrome and its emission spectra (that is, stable FITC
emitting in green versus relatively less stable APCH7 and PECy7
tandem ﬂuorochromes with emission in far red resulting in
variation due to photon-counting statistics); and (3) afﬁnity and
thus titration proﬁle of antibodies (that is, for some antibody clones
pipetting errors may lead to changes in staining levels).
The present experiment was chosen to allow analysis of distinct
populations deﬁned by positive markers in every ﬂuorescence
channel and it was designed to mimic the performance of
the antibody panels for the EuroFlow ‘small sample tube’.29
A complex, 8-color tube was chosen as testing tube to include
correct compensation in the end-point of the test. All
measurements were subjected to the previously described
EuroFlow SOPs, including analysis of merged data ﬁles using the
Inﬁnicyt software. The main question of the presented experiment
was whether biological differences between distinct cell subsets
will be resolved well when all setup procedures described so far
are used in eight different EuroFlow laboratories and when the
merged data are analyzed by the same software tools.
Standardized instrument settings and SOP evaluation
experiments
The PB of one donor was stabilized using TransFix reagent
(Cytomark, Buckingham, UK) and distributed in 1-ml aliquots to
the eight EuroFlow centers; in addition, PB samples were obtained
(after informed consent) from 30 different healthy volunteers—
that is, one PB sample distributed to all eight centers and 30
different PB samples analyzed at eight centers (three to four
samples per center). Instrument setup, compensation and sample
preparation were performed exactly as described in Sections 2, 3
and 4, respectively. Reagents used for staining were modiﬁed from
one of the 8-color EuroFlow panels (that is, SST)29 as follows:
CD20-PacB (eBiosciences, San Diego, CA, USA), CD45-PacO
(Invitrogen, Carlsbad, CA, USA), CD8-FITC, CD27-PE (ExBio,
Prague, Czech Republic), CD4-PerCPCy5.5, CD14-APC and CD3-
APCH7 (all from BD Biosciences) and CD19-PECy7 (Beckman
Coulter). After acquisition in the ﬂow cytometers, data were
exported as FCS 3.0 data ﬁles. At each center, the following cell
subsets were gated: SSClo/CD45hi total lymphocytes, CD14þ /
CD45hi monocytes, CD20hi/CD19þ B-lymphocytes, and CD3þ /
CD27þ memory T-lymphocytes with both CD3þ /CD4þ T-cells
and CD3þ /CD8hi T-cells. Then the MFI values obtained for
individual markers were calculated and reported (Table 10 and
Figure 13a). Subsequently, both MFI values and the original
listmode data ﬁles were sent to one center (DPH/O, Prague, Czech
Republic) for central analysis. Then, the CV of the MFI values
obtained for each subset in each channel was calculated. In
addition, listmode data ﬁles were merged with Inﬁnicyt software
(version 1.3), monocytes were gated as CD45hi/CD14þ cellular
events and total lymphocytes were gated as FSClo/SSClo/CD45hi
events and their subsets further deﬁned as listed in Table 10. Next,
the merged ﬁle was displayed in an APS view (PC1 versus PC2),
where each subset was color-coded, and the median of each
subset was depicted as a color-coded circle as illustrated in
Figures 13b and c.
Comparison of data obtained at each of the centers showed that
instrument-related differences caused a CV of target MFI values of
o5.5% (see Section 2 and Table 10). When a stabilized PB sample
obtained at one center was stained, measured and analyzed manually
at each of the eight centers, CVs for the MFI values of each cell
population evaluated were systematicallyo44%. Similarly, a maximal
CV of 44% for CD3-APCH7 on T-cells was observed for normal PB
samples obtained, stained, measured and analyzed at each individual
center. Notably, CVs below 17% were obtained for 4/8 ﬂuorochrome-
conjugated markers assessed in speciﬁc cell subsets. Merging all
listmode data ﬁles, followed by gating on the different subsets of
lymphocytes and monocytes showed that we were able to clearly
distinguish clusters of PB events corresponding to the same cell
subsets from samples drawn from different donors, stained at
different centers and measured on different instruments (Figures 13a
and b). This illustrates that biological differences are not hidden or
affected by the technical variability. To test the feasibility of merged
data analysis across ﬂow cytometry platforms, we acquired the same
tube (except for CD14-APC) on LSR II and CyAn ADP instruments. Both
the conventional analysis of dot plots (Supplementary Figure 1A) and
graphical analysis of the APS view (Supplementary Figure 1B) showed
separation of major lymphocyte subsets.
CONCLUSION
Our collective experiments showed that standardized instrument
settings, compensation procedures, staining protocols and data
analysis in multi-institutional collaboration programs are feasible.
Data variation resulting from hardware differences (optical
Table 10. Overall results of synchronized experiments expressed in terms of variability obtained in the 8 EuroFlow laboratories for the measurement
of antigen expression profiles in normal PB monocytes and lymphocytes (n¼ 30 different samples), stained, prepared and measured in all 8 centers
in parallel versus a stabilized sample obtained in a single center, distributed and then stained, prepared and measured locally at each center
Channel PacB PacO FITC PE PerCPCy5.5 PECy7 APC APCH7
Target MFI (Rainbow beads) 195 572 231 265 59 574 101 900 216 064 27 462 176 780 56 437
Mean actual MFI (Rainbow beads) 193 109 225 152 59 003 100 763 215 596 27 639 176 190 56 610
CV of Rainbow MFI 5.4% 4.6% 2.1% 2.4% 2.1% 3.1% 1.7% 2.2%
Antibody conjugate evaluated CD20 CD45 CD8 CD27 CD4 CD19 CD14 CD3
Gating parameters and cell subset CD20hi/
CD19þ
B-cells
CD45hi
total
lymphocytes
CD3þ /
CD8hi
T-cells
CD3þ /
CD27þ
memory
T-cells
CD3þ /
CD4þ
T-cells
CD20hi/
CD19þ
B-cells
CD45hi/
CD14þ
monocytes
CD3þ
T-cells
MFI CV for the cell subset (n¼ 8 for 1
stabilized sample)
15.2% 13.9% 11.4% 32.9% 24.7% 11.1% 43.8% 38.7%
MFI CV of the cell subset (n¼ 30
samples)
16.9% 15.5% 16.9% 28.0% 28.4% 15.4% 22.7% 48.4%
Abbreviations: APC, allophycocyanin; Cy7, cyanin7; CV, coefficient of variation; FITC, fluorescein isothiocyanate; MFI, mean fluorescence; H7, hilite7;
PacB, pacific blue; PacO, pacific orange; PB, peripheral blood; PE, phycoerythrin; PerCPCy5.5, peridinin–chlorophyll–protein–cyanin5.5.
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elements might have different quality; in some channels different
ﬁlters are used on LSR II and FACSCanto II instruments) or variation
from other sources is negligible when compared to biological
differences between cell types. However, initial training of local
operators in the applied SOPs is strongly recommended.
DISCUSSION
In constructing the EuroFlow antibody panels for the diagnosis
and classiﬁcation of leukemias and lymphomas using X8-color
ﬂow cytometry, among all technical issues, selection of the
most adequate and feasible combination of ﬂuorochromes to be
used in the available multicolor ﬂow cytometers was a pre-
requisite. Usage of an increasingly high number of ﬂuorochromes
is associated with an exponential increase in the amount of
information obtained from a single combination of ﬂuorochrome-
conjugated antibodies. However, such multicolor/multi-marker
approaches are associated with an increasing complexity and the
need to select the most appropriate/optimal combinations of
individual reagents, including compatible ﬂuorochromes for which
the required high-quality antibodies are commercially available.
As stated above, several ﬂuorochromes were pre-selected because
of the extensive experience and proven utility of a high number of
good-quality antibody conjugates and their match with the
Figure 13. Results of synchronized EuroFlow experiments performed on different centers and instruments. (a) Box plot representations of
mean fluorescence intensity (MFI) values observed for all antigens evaluated in the eight gated subsets of peripheral blood (PB) monocytes
and lymphocytes from 30 healthy donor PB samples. Results corresponding to a total of 30 merged data files are displayed. (b) Principal
component (PC)1 versus PC2 view (automatic population separator (APS) 1 view) of individual cellular events of the cell populations depicted
in a; the median values of each gated subset (circles) are color-coded as follows: B-cells, red; CD4þ /CD27þ memory T-cells, light blue; CD4þ /
CD27 T-cells, dark blue; CD8hi/CD27þ memory T-cells, dark green; CD8hi/CD27 T-cells, light green; CD3þ /CD4 and CD8 T-cells, violet;
NK-cells, yellow and monocytes, orange. (c) APS1 view of a single stabilized peripheral blood sample measured in 8 different EuroFlow
laboratories for illustration of intra-donor variability (color coding is the same as in b). In a, results are displayed as box plots, where the line in
the middle represents median values, the upper and lower limits of the box represent the 75th and 25th percentiles, respectively, and the
upper and lower ends of vertical lines represent the 95% confidence interval. In b, each population is represented as a circle surrounded by
dots corresponding to median values of median expression for all immunophenotypic parameters measured and to individual cells,
respectively.
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default optical conﬁguration of the available instruments. In
contrast, for other ﬂuorochrome positions, extensive experi-
mental comparisons among different ﬂuorochrome conjugates
were required. Finally, the combination of PacB, PacO, FITC, PE,
PerCPCy5.5, PECy7, APC and APCH7 was selected. However, while
the majority of these ﬂuorochromes performed satisfactorily well,
others still require improvement (for example, APCH7). Preliminary
testing of several new alternative ﬂuorochromes (e.g., HV450,
HV500 and brilliant violet ﬂuorochromes) show promising results,
implying that they might be suited as replacements. However, for
some ﬂuorochrome positions, alternative ﬂuorochromes are not
available (or became available very recently) or they are just
conjugated with a restricted number of CD markers, which limits
their current applicability but also points to the need for further
improvements.
The technical EuroFlow approach was designed to establish and
monitor standard instrument settings to a common bright signal
placed at the same level in different ﬂow cytometer instruments.
This implies the possibility that some variation might occur in the
measurement of dim/negative signals owing to small differences
between individual instruments. However, it assures that indivi-
dual ﬂow cytometers work above their detector’s background
noise. Slight differences in laser power output, sharpness of the
optical ﬁlters’ edges and other hardware-associated variables
might account for such small deviations.32,33 In fact, we detected
higher MFI for unstained cells in the violet laser ﬂuorescence
channels at one occasion in one instrument. The violet laser of this
instrument had to be replaced by the manufacturer owing to a
low laser power delivered to the ﬂow cell. In 2008 the CS&T
module was introduced in the 6.0 version of the FACSDiVa
software.58 Please note that this module is made for automated
instrument characterization and automated calculation of optimal
voltage settings for single instruments and does not deal with
standardized multicenter setting approaches. With the CS&T
module, PMT voltages are set at a value that is 10 times the
standard deviation of electronic noise. Small differences were
found between CS&T and EuroFlow settings owing to the different
criteria for optimal setting of PMT voltages. Whereas CS&T favors
higher sensitivity for dim signals, the EuroFlow settings are
tailored to measure both dim signals and signals generated by
molecules with very high levels of expression (for example, CD38
expression on normal plasma cells). In practice, both methods (the
EuroFlow settings and the CS&T module) were associated with
optimal PMT settings and allow for an early detection of
instrument failure (for example, laser failure). Unfortunately,
automated adjustments at daily monitoring by the CS&T module
systematically require a full new compensation experiment, even
if the variation obtained for the new adjustment is as low as
±1mV with no real impact on the compensation matrix. Daily
performance of a full compensation experiment is expensive,
time-consuming and consequently inefﬁcient in diagnostic
laboratories. In addition, it is not supported by the minor
changes observed in the compensation matrix. An additional
advantage of the EuroFlow approach is its ﬂexibility and its
applicability for 8-color ﬂow cytometers from different
manufacturers. Based on the long-term stability of MFI
measurements, once-ﬁxed PMT voltages were used. We adopted
acceptance criteria for deviations of up to 15% from the target MFI
values, for instrument settings to pass during daily monitoring. A
user-friendly software tool and graphics were built into the
Inﬁnicyt software for a quick color-code assessment of any
deviation from the accepted criteria for optimal instrument
settings. The stringency of such criteria should be driven by the
purpose of standardization. In immunophenotyping of
hematological malignancies, the biological intra- and inter-
sample differences are quite high and they are not hidden or
affected by changes in ﬂuorescence intensity values of up to 30%
(EuroFlow data; not shown). As described in Section 5 with new
automated software-driven analytical approaches that
simultaneously take into account all markers and their
intensities at the same time, the relative relevance of small MFI
changes in individual markers is signiﬁcantly diminished. In
addition, we also show that these criteria can be easily met by
different instruments at different sites.
Usage of an optimal ﬂuorescence compensation matrix
is currently considered as a requirement for optimal identiﬁcation
of single- versus double-positive cells in multicolor ﬂow
cytometry immunophenotyping.37 The complexity of the
procedure designed to set up the optimal ﬂuorescence
compensation matrix depends on the speciﬁc multicolor
antibody panels. As could be predicted, single compound
dyes were represented by one ‘generic’ SAbST (one
representative marker stained in a speciﬁc cell population),
while tandem ﬂuorochromes were represented by one tube for
each speciﬁc ﬂuorochrome conjugate antibody. The only
exception to this rule was the PerCPCy5.5 tandem ﬂuorochrome.
However, it should be noted that, in contrast to PECy7 and APCH7,
PerCPCy5.5 is a tandem ﬂuorochrome where both compounds of
the tandem show maximum emission into the same bandpass
ﬁlter; this could explain why no ﬂuorochrome-speciﬁc
compensation is needed. The similar spillover values for
different PerCPCy5.5 reagents were conﬁrmed in a small-scale
experiment (data not shown).
Fluorescence compensation experiments consisting of a full set
of compensation controls (n¼ 30 tubes) represent a challenge for
time-stressed laboratories as well as a burden for laboratory
budget. Thus, the frequency of compensation could be set to a
time interval of 1 month, during which only minor deviations from
target MFI were recorded on well-performing instruments.
However, gradual 405-nm laser power failures often resulted in
signiﬁcant signal shifts that required new instrument setup and
compensation experiments, more frequently than initially
planned. Careful selection of reagents with sufﬁcient life-span,
especially with regard to tandem ﬂuorochromes, and protection of
light-sensitive reagents is crucial for acquisition of high-quality
data in the once-per-month compensation scheme. Based on the
comparison of the ﬂuorescence compensation matrices obtained
over time for the same instrument, we concluded that it is not
necessary to repeat the compensation experiment whenever both
the reagents and the signal collection on the instrument are
stable. However, the stability of tandem ﬂuorochromes is not
reliably constant for all manufacturers and it depends on the
storage and handling conditions. Our 1-month compensation
approach was feasible as judged by evaluation ofX2000 merged
PB, BM, LN, CSF and vitreous humor samples of multiple disease
categories acquired over the past 6 years (data not shown). In turn,
a software solution that would allow automated and rapid
establishment of ﬂuorescence compensation settings to experi-
ments, after PMT voltages had been adjusted to ‘Target MFI’, could
be of great help for clinical ﬂow cytometry laboratories.
Interestingly, our multicenter results indicate that such an
approach is apparently feasible, owing to the highly stable
compensation settings observed in our study at both the inter-
and intra-laboratory level.
The EuroFlow SOPs for sample preparation was developed
because of its ability to provide robust and reliable data that
meet all the criteria indicated above. In combination with the
standardized EuroFlow SOPs to deﬁne instrument settings and
ﬂuorescence compensation, it allows generation of highly
comparable and reproducible data for a single instrument and
between different instruments within the same laboratory and
between different laboratories. Such highly reproducible data are
required not only for the comparison of data obtained within the
different EuroFlow laboratories, but also for the construction of a
database with immunophenotypic data from large numbers
of patients suffering from the various subtypes of relevant
EuroFlow standardization of ﬂow cytometry protocols
T Kalina et al
2008
Leukemia (2012) 1986 – 2010 & 2012 Macmillan Publishers Limited
hematological malignancies, which can be potentially used as a
reference by any laboratory worldwide.
Until now, standardization of ﬂow cytometry in hematological
diagnostic processes remains a challenge and it is rarely achieved in
a multi-institutional setting. There have been some attempts to
standardize the analysis of minimal residual disease in multiple
study groups9,59–61 that restricted the standardization on the
analytical stage by exchanging the listmode data ﬁles. Kraan et al.62
have presented general rules for cytometer setup in clinical settings
using analog ﬂow-cytometric systems with up to four colors,
whereas Shankey et al.63 presented complete standardization of
4-color ZAP-70 investigation in three institutions. Our present study
goes further beyond the so-far-reported multi-center studies and
aims at standardization of the data to the level at which listmode
ﬁles measured in all centers can be meta-analyzed by software tools
speciﬁcally designed for this purpose. The whole process of
cytometer settings, compensation settings, ﬂuorochrome selection
and antibody panel selection was re-evaluated and fully controlled.
The need for such extensive standardization arises from the
possibilities that are brought by three-laser X8-color digital ﬂow
cytometers to measure increasingly detailed subsets in complex
cellular samples. Cell deﬁnitions using 44 colors are thought to
enhance the accuracy of rare cell detection such as used for
minimal residual disease studies. Analysis of surface/cytoplasmic
expression patterns on large cohorts of samples by computational
tools is possible only when the input data are supplied in a fully
standardized format. Sharing of knowledge and diagnosing rare
diseases will be made possible by manual or computer-assisted
analysis of data ﬁles acquired in multi-institutional cooperation.
Here again, appropriate interpretation of the data is possible only
when standardized instrument settings and controls are used, the
quality of the data is ensured, and the performance of the antibody
panels is evaluated and taken into account during analysis.
We conclude that the 6 years of extensive collaborative
experiments and the analysis of hundreds of patients’ samples
in the EuroFlow centers have indeed provided innovative
protocols, software tools and antibody panels for fully standar-
dized diagnosis and classiﬁcation of hematological malignancies.
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